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Abstract
The transport of drugs across the blood brain barrier is challenging. The use of peptide
sequences derived from viruses with a CNS-tropism is one elegant option. A prominent
example is the rabies virus glycopeptide (RVG), which is said to enable a targeted brain
delivery. Although the entry mechanism of rabies virus into the CNS is very well characterized,
it is unknown whether RVG-functionalized drug delivery systems (DDS) follow this pathway.
RVG-functionalized DDS present themselves with modifications of the RVG peptide sequence
and different physicochemical properties compared to rabies virus. To our surprise, the impact
of these changes on the functionality is completely neglected. This review explores virus-
related CNS targeting strategies by comparing RVG-functionalized DDS with regard to their
peptide modification, physiochemical properties and their behavior in cell culture studies with
a special focus on the original pathway of rabies virus entry into the CNS.
Introduction
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Introduction
In brain targeted delivery, short virus peptide sequences with a central nervous system (CNS)-
tropism have gained great popularity as a potential targeting motif [1, 2]. Although classical
CNS delivery approaches target receptors, which are directly located on the endothelial cells of
the blood-brain barrier (BBB) [3, 4], it is unknown, if drug delivery systems (DDS), which are
functionalized with virus peptide sequences, follow this pathway [2]. An interesting fact is that
for many viruses, entry into the CNS starts at the peripheral nervous system (PNS) [5]. By
entering through the PNS, viruses benefit from the tremendously long nerve tracts which enable
their transport from the periphery to the CNS via the spinal cord, circumventing the highly
regulated BBB [2, 6]. Hitherto, the question of whether the uptake mechanism into the CNS of
particles carrying only motifs of virus proteins is identical to that of the whole virus is still
unanswered.
Especially short peptide sequences derived from virus proteins, which are responsible for the
transport of the virus into the brain, are selected for the functionalization of DDS [7-9]. This
functionalization causes significant deviations from the physicochemical properties of the
original viral particle. The peptide sequences of the virus have to be modified to enable covalent
linkage to the DDS. In addition, the DDS itself has certain characteristic physicochemical
properties which could drastically change the uptake mechanism of the original sequence. To
our surprise, the impact of physicochemical properties of virus-functionalized DDS on the
targeting effect have been completely neglected so far.
One prominent strategy for virus-related CNS targeting is the use of rabies virus. Due to its
known CNS-tropism [10], rabies virus peptide sequences have a widespread application for the
modification of DDS (see table 1, 2). Although the targeted delivery to the CNS was proved by
in vitro and in vivo analyses (see table 3), the uptake mechanisms and impact of
physicochemical properties on the cellular uptake mechanism are not discussed. This is
surprising since the pathway of the rabies virus is very well known and therefore well suited
for the precise analysis of uptake patterns and transport mechanisms of virus-modified DDS.
The goal of this review is to elucidate the impact of physicochemical properties on the cellular
uptake by comparing the properties of the virus with that of rabies virus glycoprotein modified
DDS in the literature. We will start with a description of the fate of rabies virus on its way into
CNS, including a detailed description of relevant receptors with regard to the cellular uptake
mechanism. We will then review the different types of rabies virus glycoproteins available for
DDS modification with a special emphasis on the design and the physicochemical properties of
DDS. Finally, we will review in vitro and in vivo work with respect to cell uptake and brain
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tropism. By doing so we intend to contribute to a better understanding of virus-related CNS
targeting strategies.
1. Rabies virus – a role model for CNS-targeting?
1.1. Rabies virus
The reason for using rabies virus peptide sequences for CNS targeting strategies can be
explained by the pathology of rabies virus infections, which is accompanied by neuroinvasion
and neurotropism of viral particles [11]. The virus is bullet-shaped with a length of 180 nm and
a diameter of 65 nm [12]. The virion is surrounded by a lipid layer, which carries the rabies
virus external glycoprotein (RVG) [11]. RVG is organized as a trimer and covers the complete
surface of the virus. RVG consists of 500 amino acids (aa) and has two major antigenic sites
[11] and is responsible for cellular entry and virus fusion [10, 11, 13].Therefore, RVG is a prime
candidate for use as a CNS-targeting motif.
1.2. Infection pathway of rabies virus into the CNS
In accordance with the uptake mechanism of most CNS-tropic viruses, the rabies virus uses
axonal transport to reach the CNS [14] (Figure 1). The pathway of the rabies virus starts in the
periphery with the infection of a dermal or muscular wound [2, 10]. The journey to the CNS
starts directly at the neuromuscular junctions (NMJ) [9, 10, 15]. These are specialized synapses
between muscles and motor neurons, responsible for the innervation of muscles. Published data
suggests that the rabies virus follows an interesting pathway, entering the postsynaptic muscle
membrane first and not the presynaptic neurons. In accordance with uptake mechanisms of
other viruses, the first interaction with cell membranes could be mediated by electrostatic
interactions with gangliosides, lipids and carbohydrates [10, 16-22]. The nicotinic acetylcholine
receptor (nAchR) is responsible for the first entry into the muscle cells❶. It is hypothesized
that the initial entry into muscle cells is used for the multiplication of the rabies virus and,
therefore, results in a more efficient infection of the neurons❷ [10, 23]. After the infection of
muscle cells with the rabies virus, the virus spreads from the muscle into the synapse❸. The
resulting approach enables the virus to have close contact with the cell membrane. The entry
into motor neurons could again be mediated by electrostatic interactions (adsorptive-mediated)
[10, 16-22] as well as the binding at specific receptors (receptor-mediated), which are located
in the NMJ at the motor neurons ❸ [6]. Receptors, like neuronal cell adhesion molecule
(NCAM) and low-affinity nerve growth factor (p75NTR), have been described as potential
portals for rabies virus entry into the neuron.
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However, the fact that NCAM- and p75NTR-deficient mice
could still be infected with rabies [21, 24] shows that the
complexity of the entry mechanism of the virus is still not
completely understood [25]. So far, the published data clearly
reveals the involvement of nACH-, NCAM- and p75NT
receptors in the pathogenesis of the rabies virus. However, the
complete pathway is still unraveled, including the identification
of all relevant receptors needed for the uptake. For example, it
is of high interest to determine if the interaction with the
presynaptic neurons is dependent on the preceding interaction
with the nAchR, which is located at the postsynaptic muscle
cell membrane and would have hence require a specific order
of receptor interaction [25], or if rabies virus can directly enter
the presynaptic neurons [23].
Figure 1 Scheme of the long axonal transport
of rabies virus from the periphery to the CNS.
The classical pathway suggests a prior
infection of peripheral muscle cells❶. After
the binding of rabies virus to the acetylcholine
receptor (nAchR), rabies virus enters the
muscle cell and replicates❷. From here, the
rabies virus spreads into the neuromuscular
junction (NMJ). The entry into neurons is
achieved by electrostatic interactions
(adsorptive-mediated) and receptor-mediated
interactions ❸. The neuronal cell adhesion
molecule (NCAM) and the neurotrophin
(p75NTR) receptor are believed to open the
portals for rabies virus into the nervous
system ❸. Rabies virus travels in a
retrograde manner to the cell body of the
motorneurons ❹, which is located in the
spinal cord. Hereby, it is hypothesized that
either the whole virus or the capsid alone
travels to the cell body. From here, the
neurons are connected to the central nervous
system (CNS). Rabies takes advantage of this
network and moves from neuron to neuron❺-❻ until it hits the CNS.
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1.3. Rabies virus receptors
For a solid understanding of rabies virus receptor interactions, the following section provides a
deep insight into the designated receptors, starting with their structure and their occurrence and
then going into the potential receptor binding sites of the rabies virus.
The nicotinic acetylcholine receptor (nAchR) was the first receptor discovered to be
responsible for the entry of rabies virus into CNS. Its involvement in the pathogenesis of rabies
was first revealed after the intramuscular injection of mice with rabies virus. Virus antigen
could be detected 1 hour after injection by immunofluorescence at the NMJ [22]. This
observation directly reflected the pathogenesis of rabies and confirmed that the initial infection
is transmitted by the bite of an animal [22]. Lentz et al. analyzed the binding of the rabies virus
glycoprotein to the acetylcholine receptors by using the α-1-subunit [19]. The α-1-subunit
receptor belongs to the class of muscle subunits (α1, ß1, δ, ε and ϒ), which is one of three major
classes of nAchR subunits. Entry via the muscle subunit describes the classical pathway of
rabies virus with an initial muscle infection in the periphery [23]. An interesting question is if
other nAchRs could further play a role in the transport of rabies virus to the CNS by enabling
the synaptic passage between neurons [5, 17]. nAchRs are widely distributed in the nervous
system and could, therefore, serve as potential door-opener for a fast infection of the CNS.
Furthermore, the interaction of rabies virus with the α-subunit could indicate that rabies is also
able to interact with other nAchR subtypes. An important note is that the muscular subunit α1
as well as the neuronal subunit α7 can both be inhibited by the nAchR antagonist α-
bungarotoxin [17]. Therefore, some authors assume that α7 is also able to interact with rabies
virus and, therefore, might also play a role in the uptake of rabies virus into the CNS [17, 21].
Furthermore, the mammalian brain mostly contains the α4ß2 or α7 receptor subtypes. Thus, a
deeper investigation of the α4ß2 or α7 is of high interest [17, 26].
After the observation that several lymphocyte cell lines could be infected with rabies virus
strains, challenge virus standard (CVS) and Evelyn Rotnycki Abelseth (ERA) [27], M.
Thoulouze et al. analyzed RV-susceptible and non-susceptible cell lines with regard of surface
molecules, which could enable the uptake of rabies virus. They figured out that all RV-
susceptible cell lines express two isoforms of the neural cell adhesion molecule 140 and 180
(NCAM-140 and 180) on their surface. NCAM, also known as CD56, D2CAM, Leu19 or
NKH-1, belongs to the immunoglobulin superfamily and is a cell adhesion molecule. Members
of this family can be found on neurons, astrocytes, myoblasts, myotubes, activated T cells and
NK cells [24]. Due to their expression on neurons and lymphocytes, other viruses such as
Rabies virus - a role model for CNS targeting?
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adeno-, coxsackie and herpes simplex virus use NCAM for entering the CNS as well [28].
Thoulouze et al. found that the recombinant expression of NCAM in NCAM negative cells
enhanced their susceptibility to rabies virus, whereas blocking the NCAM receptor in NCAM
positive cells using antibodies led to a decrease. In addition, the mortality of NCAM-deficient
mice was compared to wild-type animals upon infection with the CVS strain of RV. A delayed
mortality was noted for NCAM-deficient mice (mean length of survival 10 d for wild-type and
13.6 d for NCAM-deficient mice). The neutralization of RV infection by soluble NCAM, which
was composed of the five immunoglobulin (Ig)-like domains and the two fibronectin domains,
proved that the ectodomain is a potential binding site for rabies virus.
p75 neutrophin receptor (NTR) was identified as another relevant receptor for rabies virus
binding. It was discovered by screening a neuroblastoma cell library for soluble RVG [29]. The
neutrophin receptor, also known as low-affinity receptor for nerve growth factor, is a type I
transmembrane protein of the tumor necrosis factor receptor family [17]. It is important during
early neuronal development and in different pathological conditions, such as neurodegeneration
and epilepsy [30]. In adults, its prevalence is limited to the peripheral and central nervous
system. The ectodomain of the receptor consists of four cysteine-rich domains (CRD). In
contrast to other members of the tumor necrosis factor family, its ligands are organized as
dimers [29]. Different CRD mutants were used to analyze the interaction between RVG and
p75NTR. These experiments revealed CRD1 is a RVG binding site, as the antigen bound to all
mutants, except those who had a deleted CRD1. Gluska et al. analyzed the interaction of
p75NTR and rabies virus with respect to the uptake into axons and tracked the transport
machinery by live cell imaging [31]. EGFP-tagged rabies virus was applied to dorsal root
ganglion (DRG) explants, which were cultured in a microfluidic system in presence of
fluorescent antibody against p75NTR. They found that both, the rabies virus and p75NTR, were
internalized together. In addition, rabies virus infection of p75NTR knockdown DRG cultures
revealed lower infection rates, which emphasizes the role of p75NTR as rabies receptor.
Furthemore, p75NTR dependent uptake causes a faster transport of rabies virus [31].
1.4. CNS entry
After the successful receptor binding on the motorneurons, the whole virus is endocytosed via
clathrin-mediated uptake [32-34]. Next, the virus is transported to the cell bodies. This transport
was described for the whole virion as well as for the capsid alone❹ [10]. It has been reported
that the rabies virus phosphoprotein, which is part of the rabies capsid, interacts with the dynein
light chain LC8 [16, 35], this interaction requires the uncoating of the rabies virus after cell
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entry. The acidic environment of the endosomal compartment leads to conformational changes
of the rabies virus glycoprotein and causes the fusion of the virus with the endosomal membrane
[16]. On the other hand, there is also evidence for the transport of the whole virion. It is based
on the assumption that the external rabies virus glycoprotein is not only responsible for the
entry into the cells, but is also a decisive factor for the long-distance transport across the axons
(intra-neuronal transport) [36]. Rabies virus travels in a retrograde manner from the periphery
to the cell body of the motorneuron❺, which is located in the spinal cord. These cell bodies
are in synaptic contact with motor centers in the brain [8, 15]. Thereafter, the chain-like
connection of neurons via synaptic junctions allows the entry of rabies virus into the CNS❺-❻. Therefore, the infection of rabies virus heavily relies on the ability of rabies virus to interact
with receptors and cell membrane structures, enabling the synaptic passage and entry into the
subsequent neuron [5]. The exact mechanism however, remains unclear [11].
2. RVG-Primary sequence and modification: from pathogenesis to use as CNS-targeting
motif
The targeted journey of rabies virus from the periphery to the brain points directly to a key
element of the virus which is responsible for its CNS- tropism, the external surface glycoprotein
RVG. This glycoprotein contains short peptide sequences, which hold the relevant information
for the receptor-interaction with the above-mentioned receptors. Nowadays, a key strategy in
designing CNS-targeted DDS is functionalizing the DDS with such uptake-relevant short
peptide sequences. Using this strategy will give us a better understanding of the pathogenesis
of rabies and allow concomitantly the transport of such systems into the CNS. With the
investigation of the receptor binding of RVG to the nAchR, Lentz et al. provided us with better
understanding of significant structural elements within the primary sequence of RVG which are
necessary for successful receptor binding. A second aspect of major interest has been the
assessment of the physicochemical properties of the peptide sequences. As rabies virus takes
advantage of the electrostatic interactions for binding to the host cell membranes, a description
of physicochemical properties is important. An interesting fact, which is often neglected is that
the functionalization of DDS requires the modification of virus peptide sequences to enable the
linkage to the DDS. These modifications could impact the sensitivity of RVG to its receptors
and its physicochemical properties. We will, therefore, shed some light on relevant peptide
sequences, their physicochemical properties and the impact of RVG modifications on their
functionality.
RVG-Primary sequence and modification
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2.1. Receptor-binding studies of RVG
The interaction of RVG with the nAchR was somewhat anticipated due to the structure
similarities of RVG to curare-mimetic snake venom toxins, which also bind with high affinity
to the nAchR [37]. The sequence alignment of the primary sequences of the snake venom toxin
Naja melanoleuca (the residues 1-71) and RVG (residues 151-237) revealed 26 matches [37].
Further Lentz et al. showed that different cholinergic antagonists, neurotoxin peptides and RVG
peptides were able to inhibit the binding of nAchR-antagonist α-Bungarotoxin to the synthetic
peptides of the α-subunit of the ray torpedo californica and human acetylcholine receptor
(residues 173-204) [37]. The IC50-values for RVG and neurotoxin peptides were comparable
to those of cholinergic agonists and antagonists. The rabies virus CVS strain residues 175-203
(CVS 29mer), a homologous segment of the RVG, was the most effective of the rabies
glycoprotein peptides in inhibiting α-bungarotoxin (1.2x10-6M and 2.5x10-6M) [37], showing
its receptor binding capabilities to nAchR.
2.2. Physicochemical properties of RVG peptide
The physicochemical properties of RVG play an important role in the cell uptake behavior of
the rabies virus. The peptide has a good water solubility with an isoelectric point at pH 9.7,
causing a positive net charge under physiological conditions. The positive charge of RVG at
pH 7.4 explains the adsorptive interaction of rabies virus in addition to the receptor-mediated
uptake [17, 21, 22, 24]. Since heparan sulphate proteoglycans lead to a negative charge of the
plasma membrane surface, the uptake of positively charged substances is believed to be driven
by the electrostatic interactions[1, 38].
2.3. RVG-peptide modifications
For CNS targeted delivery, DDS have frequently been functionalized with RVG peptide. The
anchoring of RVG on a DDS is one of the most critical steps during formulation. The
functionalization requires modifications of RVG to enable covalent coupling or adsorption of
the peptide to the DDS. The different modifications of the RVG peptide and resulting changes
of physicochemical properties are explained in detail hereinafter. Table 1 lists the RVG
derivatives that have been used to date.
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Table 1: Peptide properties of RVG-29 peptide and its modifications estimated by peptide calculator of Innovagen.
Mod.=modification, N= number of residues, MW= molecular weight, pI= isoelectric point, dR= D-arginine; RVG-29= rabies virus glycopetide29mer; C= cysteine; G= glycine; R= Arginine; H= Histidine; GST= glutathione.
2.3.1 Addition of positively charged peptides
RVG peptides have frequently been conjugated to nucleic acids. In this strategy, the RVG
peptide acts as a navigator, leading the complex to the CNS. Because nucleic acids carry a
negative charge, they can be utilized to form electrostatic complexes with positively charged
peptides.
Therefore, by adding positively charged residues to the RVG sequence, the resulting peptide
forms complexes with nucleic acids. An example is the complex formed by attaching the cell-
penetrating peptide (CPP) nona arginine to the C-terminal of the RVG peptide sequence [48,
49]. The addition of nona-arginine leads to an increase of the isoelectric point and a positive
net charge. The construct is positively charged even at neutral pH values. Nucleic acids can be
condensed and complexed by such molecules. A short sequence of glycine or histidine serves
as a linker between RVG and nona-arginine, minimizing undesired interactions. The RVG part
of the whole molecule is still available for the receptor-interaction [47-49, 51, 54, 55, 60]. The
addition of the positively charged nonapeptide favors not only the adsorption of nucleic acids,
but also facilitates the cell uptake of the DDS [57].
The increased uptake of nona-D-arginine RVG compared to nona-L-arginine RVG was shown
by Zeller et al [57]. The use of racemic arginine led to a higher resistance against proteases and
showed reduced toxicity [57, 61]. Therefore, racemic arginine is promising for the use as CPP
for brain delivery.
Beside short oligonucleotides, Ye et al. aimed to formulate DNA-complexes with RVG. They
used the protamine RVG instead of the nona-arginine peptide, as nona-arginine RVG was not
able to bind their DNA [56].
RVG peptide sequence+
Linker
Mod. N MW [g/mol] pI [pH] Net charge
at pH7
Ref.
RVG 29 3267 9.7 2 [39-42]
RVG+C
C-T
erm
ina
l
30 3370 8.75 1.9 [3, 43-45]
RVG+GGGGC 34 3542 8.75 1.9 [46, 47]
RVG+GGGG9dR 41 4844 12.25 11 [48-53]
RVG+HHHH
rRrRrRrRr 42 5221 12.25 11.3 [54]
Recombinant fusion protein
GST-RVG29-9R-His 47 5666 12.25 11.5 [55]
RVG-Protamine 54 6458 12.17 14 [56]
RVG+9D/LR 41 4844 12.25 11 [57]
RVG+ Biotin 29 3267 9.7 2 [58, 59]
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2.3.2 Maleimide-thiol-coupling
Besides the modifications of RVG with positively charged peptides, further modifications by
coupling RVG peptide directly to DDS were undertaken. One of the most well-known coupling
reactions is the maleimide-thiol-coupling. Maleimides react with thiols to form stable thio-ether
bonds [62]. One reason for the popularity of this coupling reaction is that peptides can easily
be functionalized with cysteines to introduce a thiol group [63]. An interesting fact is that the
original RVG sequence already contains a cysteine residue, which is located in the middle of
the sequence and amenable for maleimide-thiol coupling [39, 40]. A coupling reaction with this
native cysteine could, however, impact the binding affinity of the RVG peptide to the described
receptors.
Evidence of the importance of this cysteine for the receptor binding was given by Lentz et al.
The native cysteine belongs to the matches, which have been identified via the sequence
alignment of the RVG sequence and the snake neurotoxin peptide sequence [37]. Therefore,
this cysteine could be involved in the receptor binding. Further the results of Lentz et al. imply
a reduced receptor interaction for RVG peptide sequences without cysteines in their primary
sequence. A good example is the RVG peptide CVS-10 mer, which consists of the residues
190-199 of the CVS strain and contains no cysteine. Compared to the CVS-29, which contains
a cysteine in the middle of the sequence, CVS-10 mer showed a decreased binding to synthetic
peptides of the Torpedo and Human acetylcholine receptor α-subunit with IC50 values of
7.2x10-5M, compared to 1.2x10-6M for the CVS-29 mer [37]. To avoid such a loss of receptor
affinity, one elegant approach is to modify the peptide with an additional cysteine on the C-
terminal site [43-46, 64-66]. A disadvantage of this strategy is the risk of obtaining undesirable
side products. Furthermore, if the central cysteine is not protected, the maleimide group is able
to react with both cysteines. In addition, the presence of the two cysteines may facilitate
disulfide-bond formation that decrease the number of free thiol-groups.
2.3.3 Biotin/streptavidin coupling
Chen et al. used biotin/streptavidin coupling for the attachment of RVG to albumin
nanoparticles [59]. Streptavidin mediated the linkage between RVG by carrying an additional
biotin on C-terminal, and the nanoparticles. Since the interaction between streptavidin and
biotin is one of the strongest non-covalent interactions with a dissociation constant of 1.3x10-
15M, it is very well suited as conjugation technique [67].
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2.3.4 Control peptides
To verify the receptor-mediated uptake of RVG-functionalized DDS, a comparison of these
delivery systems to negative controls is mandatory. In the literature two different examples, the
RV-Matrix peptide and scrambled RVG, have been used. Their length and physicochemical
properties are similar to that of the RVG peptide. However, they are supposed to have no CNS-
targeting effect. While the RV-Matrix peptide was obtained from rabies matrix virus protein
[48, 50-53, 56], the scrambled RVG peptide was synthesized by changing the amino acid
sequence [49].
Table 2 gives detailed information of the published rabies virus glycopeptide (RVG-29) targeted drug-delivery-systems (DDS).
By screening all DDS with regard to formulation type, RVG-29-modification and modification type, use of negative control
and cargo, the table gives an overall view and comparison of the common DDS. Furthermore, the table provides information
about the physicochemical characterization including conjugation yield, size, surface charge and stability analysis.
+ GGGG9dR= RVG-29 + glycine  linker + nine arginine residues; +C= RVG-29 with additional cysteine on C-terminal;
+GGGGC = RVG-29 + glycine linker with additional cysteine on C-terminal; +HHHHrRrRrRrRr= RVG-29 + histidine linker
+ nine arginine residues; AFM= Atomic force microscopy; Asp= Aspartate; BCA= bicinchoninic acid; BPEI= bioreducible
polyethylenimine; CD= cyclodextrins; CPT= Camptothecin; DIR= 1,2´-Dioctadecyl-3,3,3´,3´-
Tetrematheylindotricarbocyanine Iodide; DLS= Dynamic light scattering; DNA= desoxyribonucleic acid; DSPE= 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine; DTT= Dithiothreitol; EDC= 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide;
FBS= fetal bovine serum; FRET= Förster resonance energy transfer; Glu= Glutamate; GSH= gluthation; GTA= methoxy PEG
and trimethylammonium groups; ITZ= Itraconazole; miRNA;= microRNA; mPEG-Mal= Monofunctional PEG Maleimide;
n.t= not tested; N/P-ratio=  nitrogen/phosphate ration; NC= nanocarrier;; NR= nanorod; NHS-PEG-Mal/ Mal-PEG-SCM= N-
hydroxy-succinimid-polyethylene glycol-maleimide; NMR=Nuclear magnetic resonance NR= Niele red; PAH=
polyasparthydrazide; PAM-ABP= poly(cystaminebisacrylamidediaminohexane) grafted with 9–11 residues of the amino acid
arginine with a molecular weight of ∼4.45 × 10 3 Da/mole; PAMAM= polyamidoamine; PBS= Phosphate buffered saline;
PCR= polymerase chain reaction; pDNA= plasmid DNA;PEG= Polyethylenglycole; PLGA= poly (lactic-co-glycolic acid;
RPMI=Roswell Park Memorial Institute RVG-Mat= RVG-Mat (MNLLRKIVKNRRDEDTQKSSPASAPLDDG); RV-Mat=
rabies virus matrix protein; SCM-PEG-Mal- Maleimide PEG succinimidyl carboxymethyl; Scrambled RVG-
(WESYRTRAIPKCSPGTDPMINPFTRGNGN); SDS-PAGE= sodium dodecyl sulfate polyacrylamide gel electrophoresis;
siRNA= small interfering RNA; SMPT= 4-succinimidyloxycarbonyl-α-methyl-α-[2-pyridyldithio]toluene; SNALPs= stable
nucleic acid lipid particles; SSPEI= disulfide crosslinked bioreducible polyethylenimine; TMC= trimethylated chitosan; w/o=
without; w= with; wt= weight; wt= wild type.
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No
.
RVG peptide
sequence
Neg.
cont
rol
DDS Cargo Conjugationyield Linker Size Surface charge
Agarose gel
electrophoresis Serum stability Ref.
1
Ele
ctr
ost
atic
 int
era
ctio
n
RVG -
RVG-
conjugated
BPEI
pDNA
Fluorescence activity
of tryptophan:
RVG:BPEI-SH
(molar ratio 1:11,8)
GPC analysis
NHS-
PEG5k-
Mal
≥4 wt ratio size decreased to
200 nm
Neutral surface
charge at ≥4
BPEI-SS-PEG-
RVG was able to
form
polyelectrolyte
complexes with
pDNA at wt ratio
of 0.75
Stable in 10% serum in RPMI
at 37°C over 48h;
Stable up to 50% serum RPMI
in size and surface charge
[40]
2 RVG -
RVG-
conjugated
SSPEI
miRNA n.a
NHS-
PEG5k-
Mal
Polymer/miR-124a wt of 6.6 :
290.5 nm
6.6 wt ratio
(polymer/miRNA)
change to positively
charged values
0.8-6.6 wt ratio
(polymer/miRNA)
form stable
complexes
6.6 wt ratio polymer/miRNA
complexes were incubated with
10 % FBS remained stable over
4 h
[39]
3 +C -
RVG-peptide
linked
siRNA/TMC-
PEG
siRNA
1H-NMR 26% (by
weight)of RVG-
peptide linked to
TMC-PEG
Mal-PEG-
SCM
N/P-ratio from 96/1 to 12/1:
308±16 nm to 134±19 nm
siRNA loading prior to RVG-
linkage: 135±7 nm
siRNA loading after RVG-
linkage: 207± 2 nm
N/P-ratio from 96/1
to 12/1: 9.0±2.5 mV
to 4.6±1.3 mV
Stable complexes
formed at N/P ratio
of ≥48/1 and ≥24/1
Incubation with 50% serum for
72 h [43]
4 +GGGGC -
PAM-ABP:
poly (amido
amine)
PAMAM
dendrimer
grafted with 9-
11 arginine
residues
pDNA
Possible coupling
products RVG linked
C-terminal or with
Glu and Asp residues
1,2 and 3 molecules
of RVG conjugate
with each PAM-ABP
molecule at
peptide:polyplex
conjugation ratios of
2,4 and 8 detection
of thiol group by
Ellman´s assay
EDC-
NHS via
Carboxy-
group at
Arginin-
residues
of PAM-
ABP
Size decrease in dependence
of carrier:DNA ratio (520)
from 188±9 nm to 152±9 nm
for the Bare-nanocarriers,
other NC similar results in
size decrease
Increase of surface
charge in
dependence of
carrier:DNA ratio
(520) from
11.4±1.8 mV to
21.1±3.8 mV
RVG-PAM-ABP
(ratio 2:1)
complete
condensed at a 3-
fold ratio of
carrier:DNA,
peptide:polymer
ratios of 4:1 and
8:1
Environment-Sensitive DNA
release: 5mM DTT (reducing
agent) 70% of DNA was
released in 2 hours
[46]
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No
.
RVG peptide
sequence
Neg.
cont
rol
DDS Cargo Conjugationyield Linker Size Surface charge
Agarose gel
electrophoresis Serum stability Ref.
5
Ele
ctr
ost
atic
 int
era
ctio
n
+C -
Polyion
complex RVG
peptide tagged
PEGylated
polyaspart-
hydrazide
derivatives
siRNA Fluorescence intensityof tryptophan: molar
ratio of conjugate
RVG to PEG 0.32:1
SCM-
PEG-Mal
COOH-PEG-g-PAHy-GTA/si
RNA (100:1): 221±9.35 nm
RVG-PEG-g-PAHy-
GTA/siRNA (100:1):
248±10.32 nm
COOH-PEG-g-
PAHy-GTA/si RNA
(100:1): 2.78±1.82
nm
RVG-PEG-g-PAHy-
GTA/siRNA
(100:1):
9.81±3.74 nm
>50:1 COOH-
PEG-g-PAHy-
GTA/siRNA with
PEG 1/3/5% were
able to complex
siRNA 3% PEG
micelles were
chosen for further
studies
50% FBS at 37°C siRNA was
protected more than 24h [44]
6 +C -
PAMAM-PEG-
RVG29/
DNA Nano-
particles
Plasmid
pEGFP-
N2
NMR NHS-PEG-Mal 150±16.7 nm -
Complete
encapsulation at
ratio of 10:1 of
PAMAM to DNA
- [45]
7 +C -
Dendigraft-
Poly-Lysine-
RVG29-FRET
Nano-device
UV-absorbance Sulfo-LC-SMPT
DLS: ~5 nm
AFM:30 nm - -
Incubation in serum, GSH at
37°C, Activated caspase 3 at
37°C for 2 h
[3]
8 +C -
Modified β-
cyclodextrins:
cationic
amphiphilic CD
and neutral
PEGylated
derivative
1HNMR: estimated by
number of
maleimides in the
intermediated species
 4 RVG peptides
conjugate per
cylcodextrin molecule
SMPT
Coformulation of CD1 with
CD2 and RVG
CD1:CD2:CD4 Increase in
size >200 nm, PDI <0.4
Charge decrease
from 35 – 20 mV
CD1:CD2:CD4
(molar ratio
1:1.5:0.5)
complexed with
siRNA mass ratio
(1:10)
Aggregation in 50% OptiMEM
of CD:siRNA (mass ratio 10)
nanocomplexes no size
increase for complexes with
higher molar content of CD2
Incubated with 50% FBS
protection up to 24 h
[65]
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No
.
RVG peptide
sequence
Neg.
control DDS Cargo
Conjugation
yield Linker Size Surface charge
Agarose gel
electrophoresis Serum stability Ref.
9
Ele
ctr
ost
atic
 int
era
ctio
n
+GGGG9dR RV-Mat
siRNA-RVG-
9dR siRNA n.a none n.a n.a
RVG-9dR was able
to bind siRNA in
dose dependent
manner
stable over 8h in 50% FBS [48]
10 +GGGG9dR
Scramb
led
RVG
siRNA-RVG-
9dR siRNA n.a none n.a n.a n.a n.a [49]
11 +GGGG9dR RV-Mat
Liposome-
siRNA-
peptide
complexes
siRNA n.a none
siRNA:liposomes:
RVG-9r
(100:10/100/1000:1000 pmol
 178±20 nm
siRNA:liposomes:
RVG-9r
100:10/100/1000:10
00 pmol
6.25±0.75/9.78±0.
98/ 19.89±4.46 mV
(with increasing
concentration of
liposome)
n.a
Incubation with 90% mouse
serum at 37°C addition of
100 pmol prevent degradation
for at least 4 hours
[52]
12 +GGGG9dR RV-Mat
RVG9R-
siRNA siRNA n.a none n.a n.a n.a n.a [51]
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No
.
RVG peptide
sequence
Neg.
cont
rol
DDS Cargo Conjugationyield Linker Size Surface charge
Agarose gel
electrophoresis Serum stability Ref.
13
Ele
ctr
ost
atic
 int
era
ctio
n
GGGG+9dR RV-Mat n.a n.a n.a none n.a n.a n.a n.a [50]
14 +HHHH
rRrRrRrRr
- RVG-9rR/pDNA pDNA n.a none
N/P ratio: ≥3 80 nm
(Size of naked pDNA was
308±24 nm)
N/P ratio: ≥ 2 27
mV
Complete
encapsulation of
pDNA at N/P ratio:
≥3
Stability proved after
Incubation with 10% serum for
20 min by gelelectrophoresis
[54]
15
Recombinant
fusion protein
GST-RVG29-
9R-His
- RVG29-9R-6His/pDNA pDNA SDS-PAGE none
N/P ratio: ≥ 2 118-172 nm
(Size of naked pDNA was 323
nm)
N/P ratio: ≥ 2
14.2 mV
Complete
encapsulation at
N/P ratio: ≥ 2,
(shielding of
surface charge with
mPEG-Mal)
Stability proved after
incubation with 10/30/50 and
90% mouse serum in 0.01M
PBS for 4 and 8 h at 37°C
[55]
16 RVG-Protamine
RV-
Mat
RVG-
protamine-DNA
complexes
pDNA n.a none n.a n.a
Complete binding
at a w/w ratio
DNA/RVG-
Protamine of 1:10
n.a [56]
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.
RVG peptide
sequence
Neg.
control DDS Cargo
Conjugation
yield Linker Size Surface charge
Agarose gel
electrophoresis Serum stability Ref.
17 RVG+9D/LR -
RVG-9DR-
siRNA
And RVG-
9LR-siRNA
siRNA n.a none
RVG-9DR-siRNA:
208.6±20.4 nm
RVG-9LR-siRNA=203.5±3.5
nm
RVG-9DR-siRNA:
24.2±0.3 mV
RVG-9LR-
siRNA=28.8±0.7
mV
Complete binding
at Peptide-siRNA
complexes (100
pmol; 10:1
peptide:siRNA)
Both complexes stable for at
least 3 hours exposed to RNase
A; after incubation with 50%
human AB serum only RVG-
9DR-siRNA complex remained
stable over 24h in contrast to
RVG-9LR-siRNA (3h)
[57]
18
Cy
ste
ine
 mo
dif
ica
tio
ns
+GGGGC -
RVG peptide
conjugated
pluronic-
based nano-
carrier
w and w/o
chitosan
β-
Galact
osidase
1HNMR and
Fluorescence intensity of
tryptophan : 81% (1.8
wt% of the nanocarrier)
NHS-
PEG-Mal
(MW
2.1K)
Size was measured at
4/25/37°C:
At 37°C <70 nm
At 25°C:
Bare-NC: 2.1±1.3
mV
Chito-NC: 12.8±2.4
mV
RVG-Bare-
NC:1.9±2.4 mV
RVG-Chito-
NC:11.3±0.6 mV
-
β-Galactosidase release: loaded
nanocarrier in dialysis
membrane (300 kDa) in PBS
with 10%FBS 100 rpm at 37°C
[64]
19 +Biotin - PLGAnanoparticles
Campt
o-
thecin
-
Avidin-
Biotin-
Linkage
RVG-PLGA-DiR : 188 ± 44
nm
RVG-PLGA-NR:
162 ± 64 nm
RVG-PLGA-CPT:
204 ± 45 nm
RVG-PLGA:
253 ± 69 nm
RVG-PLGA-DiR :
0.36± 1.76 mV
RVG-PLGA-NR:
-0.88± 2.98 mV
RVG-PLGA-CPT:
-2.50± 1.19 mV
RVG-PLGA:
-2.71± 1.33 mV
- Incubation in PBS+ 2% Tween-80 at 37 °C [58]
20 +GGGG9dr
RV-
MAT-
9r
SNALPs siRNA
BCA Protein Assay:
12.2± 1.9 nmol RV-Mat-
9r/µmol
15.8±0.2 nmol RVG-9r
DSPE-
PEG-Mal
RV-Mat-9r liposomes : 190.0±
22.9 nm (PDI: <0.3)
RVG-9r liposomes: 195.8± 4.5
nm (PDI: <0.2)
- -
Incubation at 37°C in presence
of RNase (0.01 or 0.1 mg/ml)
or serum (10%FBS)
[53]
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RVG
peptide
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Neg.
cont
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Linker Size Surface charge Agarose gel
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21 +C -
RVG peptide
modulated
liposomes
Protamine-
condensed
siRNA
- DSPE-PEG-Mal 91±6 nm -21.8±1.7 mV n.a n.a [66]
22
Ex
oso
me
s
RVG - RVG targetedexosomes siRNA - n.a n.a n.a n.a [42]
23 RVG - RVG targetedexosomes siRNA Quantitative PCR
Lamp2b
fused to
RVG
peptide
~80 nm n.a n.a n.a [41]
24
Bio
tin
yla
ted
 RV
G
+Biotin -
RVG29-
anchored
nanoparticle
Itra-
conazole
n.a Strept-avidin-
biotin
RVG29-ITZ-NPs: 89.3 ± 1.9
nm -33.1±0.9 mV n.a Drug release in 10% FBS [59]
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3. RVG-functionalized DDS
RVG was used as a CNS targeting motif in a wide variety of DDS. These DDS differ from each
other in their different RVG peptide modifications, the type of DDS functionalization as well
as the physicochemical properties of the resulting DDS. Table 2 gives a summary of the
published RVG-functionalized DDS, providing detailed information on their formulation,
design and characterization. The main characteristics of the materials with respect to
composition and therapeutic potential will be discussed below.
3.1. Nucleic acid-RVG-polymer-complexes
RVG peptide was used for the non-viral delivery of genes to the CNS using cationic polymers
for nucleic acid complexation. Complexes with nucleic acids are formed by electrostatic
interactions of positively charged polymers and negatively charged nucleic acids, leading to the
formation of so-called polyplexes. Disulfide branched polyethylenimine (PEI) [39, 40],
trimethylated chitosan [43], poly(cystaminebisacrylamidediaminohexane) grafted with 9-11
residues of arginine (PAM-ABP) [46], polyasparthydrazide [44], polyamidoamine [45], poly-
L-lysines [3] and β-modified cyclodextrins [65] have all been used as polycationic material for
complexation with nucleic acids. The attachment of the peptide to the polymer was carried out
via the use of heterobifunctional linkers such as N-hydroxy-succinimid-polyethylene glycol-
maleimide (NHS-PEG-Mal) [39, 40, 44, 45, 43], (4-succinimidyloxycarbonyl-α-methyl-α-[2-
pyridyldithio]toluene) (Sulfo-LC-SMPT) [3] or 3-(Maleimido)propionic acid N-succinimidyl
ester [65]. Amine-reactive NHS ester enabled the coupling to the polymer, whereas a maleimide
or pyridine-2-thione functionality was used for the covalent coupling of the RVG sequence.
Besides the original RVG sequence [39, 40], RVG sequences with an additional cysteine [3,
43, 44, 65] have been used for the formation of nucleic acids-RVG-polymer-complexes. The
impact of the use of the native cysteine for the coupling reaction has already been discussed
above (see 2.3.1).
Another strategy was employed by Beloor et al., who used 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC)/NHS as coupling agent to activate the carboxy
group of the C-terminal of RVG peptide and bind it to the arginine residues on a polymer [46].
However, it cannot be excluded that the free carboxy groups of glutamate and aspartate in the
RVG sequence can react with the polymer as well. This could result in a variety of orientations
of the RVG peptide that could directly impact the receptor binding affinity, as each type of
reaction product results in a different presentation of RVG peptide to the receptor. Introducing
PEG-chains as a spacer between DDS and RVG reactive groups is a frequently used option.
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Furthermore, the PEGylation of DDS can increase their biocompatibility and extend their
circulation time in the bloodstream [68]. The presentation of RVG peptide on the distal end of
a PEG-chain might facilitate binding, in contrast to functionalized DDS without spacer. This
was shown for antiHER2 antibody fragments (Fab´) targeted liposomes [69, 70].The
quantitative analysis of the final amount of RVG peptide was estimated by different analytical
approaches. Son et al. used the fluorescence of tryptophan in the RVG sequence and measured
the increase in molecular weight of RVG-functionalized polymers by GPC analysis [40]. The
successful coupling could also be shown by 1H-NMR analysis by the disappearance of the
maleimide peak. The amount of RVG was calculated by integrating the 1H-NMR spectra [65,
43]. Another approach was the quantification of RVG by using Ellman´s assay to detect free
thiol groups of the cysteine in the RVG sequence [40].
Polyplexes of nucleic acids and RVG-polymer were characterized by measuring size, surface
charge and gel retardation which depends on the RVG-polymer to nucleic acid ratio. By
increasing the electrostatic interactions between nucleic acid and polymer, the size of
complexes decreased. Agarose gel electrophoresis was used to identify the required ratio of
siRNA or DNA (P) to RVG-polymer conjugates (N) or to analyze serum stability of complexes.
3.2. Nucleic acids-RVG-9R/protamine-complexes
Similar to RVG-polymer-complexes, RVG-nona-arginine or protamine conjugates are formed
by electrostatic interactions between positively charged poly-arginine or protamine sequences
and negative charged nucleic acids. The described nona-arginine sequences consisted either of
D-arginine [48, 51, 52, 57, 50], L-arginine [57] or alternating D-and L-arginine residues [54].
Ye et al. used protamine as complexing component [56]. The poly-arginine and - protamine
conjugates can be directly synthesized without the use of additional linker chemistry and are
added on the C-terminal of the RVG peptide. Similar to the polymer complexes, the formation
was characterized by the analysis of size, surface charge and gel retardation. Again, the positive
charge is a common property for all complexes.
3.3. RVG-functionalized nanoparticles
Nanoparticles have some advantages in comparison to polyplexes with respect to their stability.
The encapsulation protects nucleic acids against degradation and PEGylated nanoparticles
show prolonged blood circulation time [60, 64, 71].
In contrast to polyplexes, functionalization with RVG takes place after the formulation of
nanoparticles. The use of chitosan-conjugated pluronic-based micelles as transport system with
the additional RVG-peptide modification, enabling receptor-mediated uptake is one example
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of RVG-functionalized nanoparticles [64, 72]. To form these micelles, RVG peptide was
conjugated at the C-terminal to a NHS-PEG-Mal linker on the polymeric micelle. The
conjugation yield was estimated by 1H-NMR analysis and the fluorescence of tryptophan in the
RVG peptide sequence. The sizes of the different polymeric micelles were determined at
different temperatures to show the thermosensitive effect of the pluronic. Surface charge was
analyzed at 25°C and showed the impact of chitosan-modification of the polymeric micelles.
Bare polymeric micelles had neutral charge and showed no change in surface charge after RVG
modification and encapsulation with β-Galactosidase. However, the additional modification
with chitosan caused a shift to positive values of the polymeric micelles (~12 mV). β-
Galactosidase release was estimated in 10% FBS at 37°C. RVG peptides were presented on the
distal end of PEG-chains with free N-terminals. The additional modification of chitosan
allowed the binding via receptor and electrostatic interactions.
Cook et al. encapsulated camptothecin in RVG-functionalized PLGA particles.
Functionalization was achieved by an avidin-biotin-linkage, presenting RVG-peptide with a
free N-terminal [58]. Besides nanoparticles, RVG-functionalized liposomal formulations are
described as well. Tao et al. presented RVG-functionalized liposomes as a DDS for the delivery
of siRNA. The liposomes were composed of 1,2-dioctadecanoyl-sn-glycero-3-
phosphoethanolamine (DSPE), cholesterol (CHO) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (DSPE-PEG-2000-Mal)
[66]. Due to the thiol-reactivity of the maleimide group, coupling reactions could take place
either with the cysteine located in the middle or on the C-terminal of the RVG peptide.
Furthermore, liposomes containing positively charged phospholipids were used for the delivery
of nucleic acids. They are also referred to as stable nucleic acid lipid particles [53]. Conceicão
et al. used 1,2-dioleoyl-3-dimethylammonium-propane (DODAP) as the positively charged
lipid in their formulation. The liposomes were further functionalized with RVG-nona-arginine,
conjugated by the reaction of DSPE-PEG-2000-Mal with the cysteine located in the middle of
the RVG sequence. Another interesting approach was shown by Pulford et al. This group
encapsulated siRNA-RVG-nona-arginine complexes into positively charged liposomes to
enhance the stability of the siRNA complex [52]. In contrast to the other DDS, in this study,
the RVG-peptide was not present on the outer surface of DDS, but rather hidden by a positively
charged lipid bilayer of liposome.
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3.4. RVG-functionalized exosomes
Exosomes are natural nano-vesicles which are secreted by numerous cell types [42, 41, 73].
Because of this, they are an excellent DDS, mimicking natural cell vesicles [74]. Due to their
cell-like membrane structure, exosomes are less likely to elicit a foreign body response, thus
causing less adverse effects [74]. In the literature, two exosome formulations were presented as
promising BBB-targeted DDS for gene delivery [41, 42]. In these studies, researchers used self-
derived dendritic cells for exosome production. An advantage of exosomes is that they contain
a number of membrane proteins, which are exclusively expressed on the exosomal surface [75].
Lamp2b is one such exosomal membrane protein, which can be used to functionalize exosomes,
by fusing the RVG peptide to the extra-exosomal N terminus [41, 42]. The RVG-Lamb2b
functionalized exosomes were analyzed with regard to their size using nanoparticle tracking
analysis and electron microscopy. The successful expression of RVG Lamp2b was assessed
with quantitative PCR. Loading of exosomes was achieved with electroporation [41, 42].
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Table 3: Summary of the performed in vitro experiments of RVG-functionalized DDS. The table gives an overview of the cellular uptake studies of the RVG-modified DDS. Each DDS is listed along
with its physicochemical properties, the used cargos and cells as well as the studies performed on the cellular uptake.
No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
1 RVG-conjugated BPEI
Firefly luciferase
coding sequence
region in pcDNA3.1
(+) vector
Neuro2a (nAchR-positive)
HeLa (nAchR -negative)
RVG: unmodified
sequence
Size: ~200nm
Charge: 0
Confocal microscopy:
Higher extent of uptake of polyplexes and gene expression in Neuro2a cells than in HeLa
Competitive inhibition assay:
Free RVG peptide was able to compete the uptake of BPEI-SS-PEG-RVG/pDNA (6.4
fold decrease of gene expression)
Negative control: BPEI-SS-PEG/pDNA polyplex
[40]
2 RVG-conjugated BPEI
Cy5.5-labeled miR-
124a oligomer
CMV promoter
driven Gaussia
luciferase vector
Neuro2a (nAchR-positive)
HeLa (nAchR –negative)
RVG: unmodified
sequence
Size: 290.5nm
(Polymer/miR.124a wt
of 6.6)
Charge:+
Fluorescence intensity:
3-fold higher fluorescence activity in Neuro2a compared to HeLa
Detection of miR-124a release from RVG-SSPEI/miR-124a-complex:
Decrease of gaussialuciferase activity compared to
Negative control: RVG-SSPEI +scrambled miRNA
[39]
3 RVG-peptide linkedsiRNA/TMC-PEG
PPIL2 siRNA
Carboxyfluorescein-
labeled siRNA
Neuro2a
(nAchR-positive)
HeLa
(nAchR-negative)
RVG: +C
Size: siRNA/TMC-
PEG-RVG :~ 200nm
Charge: +
FACS:
Increase of MFI 1.6-1.8 fold compared to unmodified complexes in Neuro2a, but not in
HeLa
Negative control: siRNA/TMC-mPEG complexes
CLSM: Uptake of modified complexes
In vitro gene silencing:
Expression of BACE1 was 57% for unmodified complexes and 50% for RVG-modified
complexes
[43]
5
Polyion complex RVG
peptide tagged
PEGylated polyaspart-
hydrazide derivatives
PPIL2 siRNA
Negative control
siRNA
FAM-labeled
siRNA
Cy5-labeled siRNA
Neuro2a
(nAchR-positive)
HeLa
(nAchR-negative)
RVG: +C
Size: RVG-modified
micelles: ~ 250nm
Charge: +
FACS/CLSM:
Cellular uptake of RVG-modified micelles significantly higher in Neuro2a compared to
HeLa
Negative control: COOH-PEG-g-PAHy-GTA/FAM-siRNA micelles
In vitro gene silencing:
Reduced expression of BACE1 detected by Western Plot analysis
[44]
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No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
6 PAMAM-PEG-RVG29/DNA
pEGFP-N2 and
pGL2-control vector BCECs
RVG: +C
Size: ~150nm
Charge: n.a
Cellular uptake by fluorescent microscopy:
Cellular uptake of PAMAM-PEG-RVG29
Negative control: PAMAM-PEG/DNA
Cell uptake mechanism:
 Receptor-mediated uptake was reduced at 4°C
 Receptor-mediated uptake could be competitive inhibited by free RVG peptide
 Incubation with acetylcholine, mecanylamine and nicotine had little influence on
the uptake
 The cellular uptake was reduced after the incubation with free GABA
 Receptor-mediated uptake was reduced by the endocytotic pathway inhibitor
filipin,
Transport studies
Papp of PAMAM-PEG-RVG29/DNA NPs was higher compared to PAMAM/DNA
NPs
[45]
7 Dendigraft-polylysine-RVG29-FRET
Cy5 labeled nine
amino acid pepitde SH-SY5Y
RVG: +C
Size: ~5nm
Charge: n.a
In vitro caspase-3 activation model:
RVG-modified nanodevice was able to detect caspase-3-activity [39]
RVG-functionalized DDS
35
No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
8 RVG-Modified β-Cyclodextrins
Fluorescein-tagged
siRNA
GAPDH siRNA
U87
HeLa
RVG: +C
Size: RVG-modified
cyclodextrin formulation
(R3): ~250 nm
Charge: +
Cellular uptake in U87:
Negative control: free siRNA, cationic CD siRNA complex, PEGylated CD
Control: Lipofectamine + siRNA
RVG-tagged PEGylated cyclodextrin co-formulation R3 showed the highest uptake in
comparison to untargeted co-formulations
Competitive inhibition assay:
Preincubation with RVG results in significant decrease in uptake of targeted co-
formulations in U87 cells, no effect in HeLa cells
GAPDH knockdown analysis:
Negative control: naked siRNA, cationic cyclodextrin w/o siRNA
Positive control: Lipofectamine+siRNA
Cationic cyclodextrin siRNA nanocomplex: 80% reduction
Cationic cyclodextrin w/o siRNA : No effect
PEGylated cyclodextrin : No significant knockdown
RVG-tagged PEGylated cyclodextrrin siRNA nanocomplex: 27% reduction
[65]
9 siRNA-RVG-9dR
Biotinylated RVG or
RVG-Mat
Anti GFP siRNA
Neuro2a
(nAchR-positive)
BHK21
292T
HeLa
CHO
(nAchR-negative)
RVG: GGGG+9dR
Size: n.a
Charge: n.a
Cellular uptake of RVG-peptide:
Uptake of RVG instead of RVG-Mat in Neuro2a
Uptake of RVG in Neuro2a (nAchR positive)
No uptake in non-neuronal cell lines
Competitive inhibition of RVG by α-bungarotoxin in dose-dependent manner
Cellular uptake of RVG-9R/siRNA complexes:
Uptake of FITC-siRNA/RVG-9R complexes in a dose-dependent manner in contrast to
RV-Mat-9R/siRNA complexes
Positive control: Lipofectamine
GFP-silencing:
Lipofectamine and RVG-9R/siRNA complexes were able to decrease GFP-expression
[48]
Chapter 1 - Targeting the blood-brain barrier: a review of rabies virus targeting strategies
36
No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
10 siRNA-RVG-9dR FITC-siRNA
Raw 264.7
N9
Primary splenic
macrophages of wild
type and AchR knockout
mice
RVG: GGGG+9dR
Size: n.a
Charge: n.a
nAchR-expression:
Expression of nAchR on Raw 264.7, N9 and primary macrophages of wild type but not of
knockout mice
Cellular uptake of RVG-FITC on primary macrophages:
Negative control: scrambled RVG-FITC
RVG-FITC but not negative control showed uptake in primary macrophages of wild type mice
No uptake of FITC-RVG in primary macrophages of nAchR knockout mice
Cellular uptake of RVG-9dR/FITC-siRNA complexes:
RVG-9dR complexes transduced 90% of FITC-siRNA inN9 cells and 65% in Raw 264.7 cells
RVG-9dR complexes were able to transduce siRNA into primary macrophages of wild type mice,
but not into nAchR-knockout mice
Gene silencing in Raw 264.7 cells:
70% reduction of GFP expression
[49]
11 Liposome-siRNA-peptide complexes
PRP (cellular
prion protein)
siRNA
Neuro2a
(nAchR-positive)
HEK293
HeLa
4T1
(nAchR-negative)
RVG: GGGG+9dR
Size: ~180 nm
Charge: +
Uptake to Neuro2a (MFI):
PRP-siRNA/RVM-9r w/o liposome: no uptake
PRP-siRNA/RVM-9r w liposome: 15%
PRP siRNA-RVG-9r w/o liposome: 8%
PRP siRNA-RVG-9r with liposome: 85%
Competitive inhibition of RVG-9r with liposome in Neuro2a:
Excess of unlabeled RVG-9r or RVM-9r
Cell specificity (MFI):
PRP-siRNA/RVG-9r with liposome:
Neuro2a: 90+5%
HEK292: 67+7%
4T1 and HeLa:<5%
PrP siRNA-RVG-9r LSPC suppress expression:
PrP-siRNA/RVG-9r w liposome: 30+8%
PrP-siRNA/RVM-9r w liposome:99+3%
RVG-9r-control w liposome:98+2%
Liposome alone: 99+2%
[52]
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No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
12 RVG9R-p137 p137-RVG9r
SH-SY5Y
HEK293
U373
RVG: GGGG+9dR
Size: n.a
Charge: n.a
α3/α5nAchR-expression in SH-SY5Y, HEK293, U373:
Expression of α3/α5nAchR subunits in SH-SY5Y and U373 cells
Cellular uptake in α3/α5nAchR –positive U373 cell line
Negative control: naked siRNA, RVMat9R-p137 and RVG9R-pXef
Cellular uptake of RVG9R-p137 complexes in contrast to negative control
Protection of SH-SY5Y from rotenone-induced cell death:
Negative control: RVG9R- scrambled p137, RVMat9R-p137
Reduced cell death after incubation with RVG9R-p137-complexes
[51]
14 RVG-9rR/pDNA pEGFP
Neuro2a
(nAchR-positive)
HeLa
(nAchR-negative)
RVG: HHHHrRrRrRrRr
Size: ~80 nm
Charge: +
Cellular uptake of RVG29-9rR/pDNA in Neuro2a:
RVG29-9rR/pEGFP-N1
Negative control: 9rR/pEGFP-N1, naked plasmid
Uptake of RVG29-9rR/pEGFP-N1 in Neuro2a in contrast to negative control
No uptake in HeLa cells
Inhibition of endocytosis at 4°C
Internalization indicated by LysoTracker
Luciferase expression assay:
Positive control: Lipofectamine
RVG29-9rR delivered pEGFP in Neuro2a but not HeLa
Highest DNA efficiency at N/P ratio >3 in Neuro2A cells (55.9%)
Higher transfection efficiency compared to positive control
[54]
15 RVG29-9R-6His/PDNA
pRNAT-U6.3/Hygro
encoding green
fluorescent protein
Neuro2a
(nAchR-postive)
HeLa
BV-2
BHK-21
(nAch-negative)
RVG: +9R-6His
Size: <200 nm
Charge: +
Neuro2a cells-based ELISA:
Detection by anti-His antibodies Uptake of RVG29-9R-His/pDNA was only
detectable by Neuro2a cells but not HeLA cells
Specificity of cell recognition:
Positive control: Lipofectamine (33% in Neuro2a)
Complex was only taken up by Neuro2a cells
Transfection efficiency [%]: 28% Neuro2a, 0.9% in BV-2, 3.3% in HeLa and 3.3% in
BHK-21
[55]
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No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
17 RVG+9D/LR-siRNA GFP Neuro2a(nAchR-postive)
RVG: +9R
Size: ~200 nm
Charge: +
Cellular uptake :
Uptake of 9DR/LR (higher uptake of 9DR after 24h)
9DR-GFP higher uptake compared to 9LR-GFP
RVG-9DR/LR-siRNA complexes showed enhanced uptake in Neuro2a cells
Gene silencing (Increase of GFP-negative cells %):
Positive control: Lipofectamine
Negative control: 9DR/LR-siRNA
RVG-9LR-siRNA: 69.8 ± 2.7%
RVG-9DR-siRNA: 42.1 ± 23.4%
Lipofectamine : 46.6 ± 19%,
Cellular trafficking:
Detailed information please refer to reference
[57]
20 Brain targeted SNALPS
Si-EGFP
FAM labeled siRNA
siMutAtax3
Neuro2a
(nAchR-positive)
HT-22
HeLa
(nAchR-negative)
RVG: GGGG+9R
Size: < 200 nm
Charge: n.a
Cellular uptake:
Negative control: Non-targeted SNALPs, RV-MAT-9R targeted liposomes
Increase in uptake of RVG-9R targeted liposomes in Neuro2a and HT-22 cell line, but
not in HeLa
siRNA delivery in Neuro2a cells:
Uptake indicated of RVG-9R targeted liposomes encapsulated FAM-labeled siRNA
Uptake inhibition:
Uptake was reduced at 4°C and inhibited by free RVG peptide
Gene silencing:
RVG-9R targeted liposomes encapsulated siMutAtax3 decreased mutant ataxin-3
levels
[53]
21 RVG-peptide modulatedliposomes
FAM-labeled
siRNA
EGFP-
siRNA+Protamine
BMM
U87
RVG: +C
Size: ~90 nm
Charge: -
Cellular uptake in BMM cells:
Increase of uptake of RVG-liposomes and RVG-liposomes containing siRNA
GFP expression silencing:
Negative control: naked GFP-siRNA, RVG-liposome
Common liposome, CRGD and RVG modified liposomes encapsulated with GFP-
siRNA showed similar reduction in GFP expression ( ~ 20%)
[66]
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No. DDS Cargo Cell line Physicochemicalcharacterization Cellular uptake Ref.
22
RVG targeted exosomes
siRNA alpha-
synuclein SH-SY5Y
RVG: unmodified
sequence
Size:n.a
Charge:n.a
Gene silencing:
Positive control: Hiperfect transfection reagent
RVG exosomes showed higher efficiency than positive control
[42]
23 GAPDH siRNABACE1 siRNA
C2C12 (muscle)
Neuro2a
RVG: unmodified
sequence
Size: ~80 nm
Charge: n.a
Gene silencing:
Positive control: Lipofectamine
Negative control: naked siRNA, unmodified exosomes
GAPDH silencing could be achieved by RVG modified exosomes in Neuro2a cells but
not in C2C12
BACE1 silencing was dose dependent for RVG modified exosomes and could be
inhibited by α- bungarotoxin
[41]
24 RVG29 anchorednanoparticle Itraconazole bEND3
Cellular uptake on bEND3:
FITC-RVG29-ITZ-NP: 52.15 ± 3.41
FITC-ITZ-NP: 22.62 ± 2.51
[59]
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4. In vitro testing of RVG-functionalized DDS
In vitro testing of RVG-functionalized DDS should give us an answer of whether or not the
functionalization with RVG enables a targeted delivery into the brain. By using RVG as a CNS
targeting peptide, the functionalized DDS should follow the pathway of rabies virus. Therefore,
the cells lines and in vitro experimental designs used should reflect the pathway of the rabies
virus. The uptake mechanism of rabies virus was described as a combination of receptor- and
adsorptive-mediated uptake. According to the classical pathway of the rabies virus, especially
muscle cells and neurons are of utmost relevance, and could be therefore, used for the in vitro
testing of RVG-functionalized DDS.
4.1. Interaction of RVG-functionalized particles with primary cells and cell lines
The in-vitro effect of RVG-functionalized DDS on cells was investigated in several studies
(Table 3). Figure 2 gives an overview of the used cell lines, including their origin and receptor
expression. The uptake of RVG-functionalized DDS by neuronal cell lines, such as Neuro2a
expressing nAchR (nAchR-positive), versus to non-neuronal cell lines, like HeLa, BHK-21,
292T, CHO, HEK293, 4T1, BV-2 and C2C12 which do not express nACH-receptors (nAchR-
negative) [24, 39-41, 43, 44, 48, 52-55, 57], was investigated by a number of groups. Neuro2a
cells are derived from mouse neuroblastoma. An important question is the involvement of the
neuronal nAchR subunits. According to the classical pathway of rabies, only the interaction of
RVG with the nAchR subunit α 1, which is typically expressed in muscles cells, has been
described. The uptake of RVG-functionalized DDS in Neuro2a cells allowed researchers to
draw conclusions about the receptors relevant for the uptake of the rabies virus and RVG-
functionalized DDS, as Neuro2a cells express several neuronal nAchR subunits as well as
NCAM and p75NT receptors. Therefore, this cell line is ideal for the investigation of the cell
uptake of RVG-functionalized DDS by receptor-mediated effects [24, 76].
Although the rabies virus does not belong to the group of viruses which enter the CNS via the
BBB [5, 10, 11, 77], the uptake of RVG-functionalized nanoparticles was also assessed using
brain capillary endothelial cells (BCECs) [45] and the mouse brain endothelial cell line bEnd.3
[59]. The uptake of RVG-functionalized nanoparticles in these cell lines shed new light on the
uptake characteristics of RVG-functionalized DDS. These studies revealed RVG-
functionalized DDS also target non-neuronal cells at the BBB. The bEnd.3 is an immortalized
mouse endothelial cell line, which expresses several typical BBB transporters and receptors,
like glucose- and l amino acid transporters and the p-glykoprotein receptors as well as important
tight junctions proteins [78]. Due to its BBB functionality, this cell line is widely used for
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testing interaction of DDS with the BBB [4, 66, 79]. The observed uptake of RVG-
functionalized DDS in these cells could be a result of the involvement of further unknown rabies
receptors, but could also be due to electrostatic interactions between the RVG-functionalized
DDS and the endothelial cell membrane. Further experiments are required to create a complete
picture of the pathway of RVG-functionalized DDS.
The in vitro testing on human glioblastoma cell line U87 aimed at the application of RVG-
functionalized DDS for the treatment of cancer [51, 65, 66]. The use of the SH-SY5Y cell line
directly addresses the application of RVG-functionalized DDS in parkinson disease [3, 42, 51,
80]. The SH-SY5Y is a neuronal tumour cell line [81]. Interestingly, it expresses several
neuronal nAchR subunits, the α3, α5, β2 and β4 as well as the α7-subunit [51, 82, 83]. The α7-
subunit is the prime candidate for the receptor-binding of RVG-functionalized DDS among the
nAchR subunits. Like the α1-subunit, which was used for the receptor-binding studies of RVG,
the α7-subunit is also able to bind the antagonist α-bungarotoxin. This fact demonstrates
structural similarities between the two subunits, which might also enable the binding of rabies
virus and RVG-functionalized DDS on the neuronal α7-subunit. With regard to pathological
conditions of the brain, microglia cells play an important role as immune barrier [1, 4, 49].
Expressing the α7 subunit of nACHR on their surface, Kim et al. investigated the RVG targeting
effect on macrophages (Raw 264.7), the glial cell line (N9) as well as primary macrophages,
which were obtained from wild type mice [49]. The group used the wild-type primary
macrophages to assess the binding of the RVG peptide. The results assume that the FITC-
labeled RVG was also able to bind at the primary macrophages via the α7 subunit [49].
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Figure 2: Overview of the cells used for the in vitro testing of RVG functionalized DDS, including their location and their receptor expression.
Neuronal cell lines directly mirror the classical pathway of rabies virus along the axonal nervous system. This includes neuronal cells like the
Neuro2a and the SH-SY5Y cell lines, which are said to express several identified rabies receptors, like nAcHR, NCAM and p75NTR.Microglia
cells, like N9, play a role in the immune response of the brain and are also expressed with nAchRs. The use of brain endothelial cells directly
target a potential uptake of RVG functionalized DDS across the blood brain barrier (BBB). The mouse endothelial cell line bEnd.3 and brain
capillary endothelial cells (BCECs) have been used. In contrast to the nAchR-expressing cells, no rabies virus receptors have been identified.
This is the same for the glioblastoma cell line U-87, which shows the application of RVG-functionalized DDS in the field of cancer therapy.
4.2. Receptor-mediated uptake
The first step of the analysis of RVG-functionalized DDS should be the proofing selective
uptake of the targeting peptide RVG itself. This was impressively shown by the work of Kumar
et al., who proved the selective uptake of biotinylated RVG peptide compared to the RV-Mat
peptide, which was used as negative control, on Neuro2a cells [48]. The preliminary
investigation of the uptake of RVG peptide alone was also performed by Kim et al. They
showed that FITC-labeled RVG peptide was taken up by primary macrophages of wild type
mice. In contrast, primary macrophages of nAchR-knockout mice showed no uptake of RVG-
peptide [49].
The mechanism of receptor-mediated uptake of the RVG-functionalized DDS was analyzed by
cellular uptake studies conducted at 4°C compared to 37°C [45, 54] or by the competitive
inhibition with free RVG peptide [40, 48, 52, 65], agonists or antagonists. This was, for
instance, shown by Liu et al, who analyzed the cellular uptake of RVG-functionalized
nanoparticles BCECs. The results suggested a receptor-mediated uptake via the GABA
receptor, which was indicated by a reduced uptake after the pre-incubation with free GABA.
The prior incubation with potential inhibitors of the nACHR (acetylcholine, mecanylamine and
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nicotine) caused no reduced uptake of RVG-functionalized nanoparticles [45]. The suggested
pathway is of high interest and the involvement of GABA in the pathogenesis of rabies was not
described. Further investigations are required.
In addition to the inhibition studies, BCECs were incubated with different endocytosis
inhibitors to investigate the endocytosis mechanism. Furthermore, the nACHR-receptor-
specificity for Neuro2a was proved by the reduced uptake of RVG-peptide after the incubation
with α-bungarotoxin [48, 41].
4.3. Do RVG-functionalized DDS follow the classical rabies virus pathway?
The analysis of RVG-functionalized DDS brought new insights. The higher uptake of RVG-
functionalized DDS in neuronal cells compared to non-neuronal cells clearly revealed an uptake
mechanism that is similar to that of rabies virus. However, it is questionable whether RVG-
functionalized DDS enter the CNS via the long axonal transport system like the rabies virus.
The fact that RVG-functionalized DDS also showed cellular uptake in brain endothelial cells,
suggests that the uptake mechanism of these DDS differs from that of rabies virus. Two major
aspects have to be taken into account. First the presentation of RVG peptide on the surface on
DDS and, second the overall surface net charge. The orientation of RVG molecule on the
surface is highly dependent on the type of DDS and the selection of the RVG modification. To
our surprise, the presented data revealed that the different ways of RVG orientation on DDS
surface had no impact on the cellular uptake. Therefore, it is arguable that RVG-functionalized
DDS are endocytosed via highly selective receptor interactions. The results of Lentz et al.
clearly showed that the receptor binding affinity at the α-1-subunit depends on the primary
sequence of the RVG peptide [22]. These facts emphasize an uptake of RVG-functionalized
DDS, which is mediated via the electrostatic and hydrophobic interactions between the RVG-
peptide coupled onto the surface of the DDS and cell membranes [17]. The complete picture of
the uptake of RVG-functionalized DDS can only be given by a precise analysis of receptor
interactions.
Chapter 1 - Targeting the blood-brain barrier: a review of rabies virus targeting strategies
44
5. In vivo
The question of whether the RVG-functionalized DDS are actually up taken into the CNS is
finally answered by the in vivo analysis of RVG-functionalized DDS and was shown for most
of the presented DDS. The targeted uptake into CNS was shown for RVG-functionalized DDS
and compared to the uptake of the used cargo of the DDS [54], the unmodified DDS [39, 40,
43, 44, 66] or the used DDS functionalized with scrambled versions of RVG instead of the
CNS-leading RVG sequence [48, 52]. Besides the proof of CNS targeting by using fluorescent
cargos, active cargoes were used to detect luciferase activity [45, 54] , caspase-3 activation [3],
or the expression or silencing of genes [41, 42, 48, 52]. As the performed in vivo experiments
mainly focused on the final delivery of the RVG-functionalized DDS into the brain rather than
showing the complex fate of RVG-functionalized DDS to its final destination, the in vivo
experiments are not discussed in detail.
While Kumar et al. were one of the first to show the potential of RVG as CNS targeting motif,
the group of Cook argued the CNS targeting potential of RVG. Kumar et al. showed that mice
infected with japanese-encephalitis virus (JEV) could be treated with the antiviral siRNA/RVG-
9R complex (80% of survival). In contrast, mice treated with siRNA alone, luciferase siRNA,
or siRNA complexed with RV-MAT-9R died within 10 days. The results of Cook et al.
challenged the CNS targeting potential of RVG [58]. They quantified the delivery of the
fluorescence marker DiR, encapsulated in RVG functionalized or biotin-functionalized
nanoparticles, to the specific CNS regions. These results suggested only minimal evidence of a
targeted uptake via the spinal cord into the CNS. A higher uptake of RVG-functionalized
nanoparticles was only shown in the cortex region. This observation led to the assumption of
the participation of GABAB receptors in the entry mechanism of rabies virus, as these receptors
are mainly located in this region. Cook et al. further referred to the results of Liu et al., who
showed that the uptake of RVG-functionalized nanoparticles was inhibited by GABA in brain
endothelial cells [45]. This is an interesting hint as the GABA receptor is not described as a
rabies receptor and should, therefore, be taken into account for a deeper analysis of receptor
participation.
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6. Summary and conclusion
Rabies virus carries a decisive factor for the entry into the CNS, controlled by the external
surface glycoprotein RVG. Although the complete infection pathway of the rabies virus is still
not understood, nAchR, NCAM-1, p75NTR as well as the interaction with carbohydrates,
gangliosides and lipids hold a stake in its entry into CNS. It is assumed that the virus uses a
dual entry strategy of receptor and electrostatic interaction. This was further emphasized by the
identification of 29-mer peptide derived from RVG, binding to α-1-subunit of nAchR, and the
fact that this peptide has an overall positive charge under physiological conditions, enabling
electrostatic interactions with the cell membranes. For the functionalization of DDS, the RVG
sequence underwent modifications. The impact of these modifications with regard to the uptake
mechanism still needs to be investigated. The functionalization with RVG was applied to
several DDS like for the delivery of nucleic acids with polymer or polyarginine complexes,
nanoparticles and exosomes. The targeting effect was proved by the increased uptake of
targeted DDS in neuronal compared to non-neuronal cells. Although the classical pathway of
rabies virus is along the long axonal nervous system, the uptake of RVG-functionalized DDS
in brain endothelial cells and macrophages emphasize a versatile uptake strategy for these DDS.
The functionalization of DDS with the RVG sequence resulted in changes of the primary
sequence of RVG and in different physicochemical properties compared to RVG. Interestingly,
the uptake into the used cells was independent from all changes, which could be due to the
significance of positive charges of the molecules for the cell uptake.
Nevertheless, for the identification of the uptake mechanism of targeted DDS, impact factors
like modification of peptide and physicochemical properties should be taken into account. The
results assumed a dual-approach of receptor binding and electrostatic interactions, which cannot
be reduced to a unique key-lock principle. Although the potential CNS targeting has been
proved by in vivo experiments, they were not able to record the pathway of RVG-
functionalized DDS. Especially the contradictory results of Kumar et al. and Cook et al. showed
that is it important to record the track of RVG-functionalized DDS and taking the structure
modifications of RVG and the DDS own physicochemical properties into account.
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The use of active targeting strategies for the delivery of active pharmaceutical ingredients (API)
across the blood-brain barrier (BBB) is a common approach in nanoparticle formulation
strategies. The approach introduced here is decorating particle surfaces with specific ligands
that are able to interact with transporters or receptors located on brain endothelial cells.
However, a successful active targeting is not only achieved through the “decoration” of
nanoparticles. Although the selection of the targeting ligand is assumed to be the decisive factor
in BBB-targeting strategies, the impact of the drug delivery system (DDS) itself on the fate of
the whole system is completely neglected. This is particularly evident for virus-related CNS
targeting strategies, which gained great popularity in brain-targeted delivery. DDS
functionalized with virus peptide sequences are intended to follow the same pathway as the
virus into the CNS. However, it is questionable whether the functionalized DDS follow exactly
the same pathway. The introduction focusses on the fate of virus-functionalized DDS into the
CNS. It is intended to deepen the understanding of the virus-related CNS targeting strategies
by comparing the properties of rabies virus glycopeptide (RVG)-functionalized DDS with
rabies virus (chapter 1).
The importance of tissue-specific properties for BBB-targeted DDS was further investigated by
adjusting physiochemical properties of liposome formulations with respect to BBB
requirements. Liposomes have a high versatility with respect to physicochemical properties and
other sophisticated functionalization possibilities. Current preparation strategies and the
knowledge about brain tissue specific requirements enable the formulation of tailor-made
formulations with respect to size, surface charge or the use of the brain specific polyunsaturated
fatty acid docosahexaenic acid (DHA) (chapter 3).
The analytical characterization is a sine qua non for the development of functionalized
liposomes. The complex composition of functionalized liposomes in particular as well as their
manufacturing, which is a multi-step process, requires extensive characterization. Although a
variety of analytical techniques are available, quantitative data on the liposome composition
and the targeting ligands density are often missing. This increased the motivation enormously
to establish analytical methods for the quantification of all individual liposome components
(chapter 4).
Maleimide-functionalized phospholipids play a key role in the functionalization of liposomes
with targeting peptide sequences. The specificity for thiol-groups in combination with their fast
reaction kinetics under mild and aqueous conditions explain their popularity. However,
maleimides are prone to pH-dependent hydrolysis. This causes changes in the overall surface
charge as well as the inability to react with thiols. To understand and control maleimide
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intensity during functionalized liposomes manufacturing was, therefore, of key interest
(chapter 5).
Finally, the targeting efficiency of BBB specific liposomes was investigated by the cell-binding
studies using a brain endothelial cell line (bEnd.3). The cells were used to assess the tissue-
specific requirements of BBB specific liposomes with respect to size, surface charge or the
brain-specific polyunsaturated fatty acid DHA (chapter 6).
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Abstract 
While the majority of brain targeted drug delivery systems (DDS) uses active targeting 
strategies to reach their destination, physicochemical characteristics of these DDS are often 
neglected. This is surprising, since the passing of tailor-made DDS across the blood-brain 
barrier (BBB) requires more than an active targeting strategy. The presented work sheds light 
on important physicochemical characteristics focusing on size, charge, polyethylenglycole 
(PEG) amount and composition by the example of BBB-targeted liposomes. By the selection 
of different lipids and varying concentrations a screening platform was assembled for the 
analysis of BBB-specific physicochemical properties for liposomes. The setting of different 
sizes (from 50-405 nm) was feasible with a liposome composition of DOPC, CHO and DSPE-
PEG-2000 in a molar ratio of 60:35:5 (mol%). The preparation of positively charged 
formulations was reached with liposomes composed of DMPC, CHO and DOTAP (20 ± 4 mV). 
The degree of PEGylation, which is of high importance for the functionalization of liposomes, 
could be increased up to 10% (mol/mol) of the total lipid concentration. Docasahexaenoic acid 
proposed as brain specific could successfully be incorporated into liposome formulation. The 
presented work provides important information in terms of BBB targeted delivery systems 
beyond the standard ligand coupling procedures.
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1. Introduction 
The targeted delivery across the blood-brain barrier (BBB) requires tailor made drug delivery 
systems (DDS). The published literature mainly deals with active targeting strategies [1, 2]. 
Whereby, the aim is to deliver DDS into the brain by attaching receptor-sensitive ligands on 
the surface of DDS. By this, the attached ligand is able to interact with receptors, located on the 
endothelial cells, and therefore induce receptor-mediated uptake into the brain [1]. While the 
uptake of these BBB targeted DDS is explained by the selection of the brain-specific ligand, 
the impact of physical and chemical DDS characteristics like size, charge and composition on 
brain uptake is completely overlooked. This is astonishing, as the biological characteristics and 
highly regulated uptake mechanisms of the BBB require tailor-made properties of BBB-
targeted DDS [3-5]. Therefore, not only the selection of targeting ligand, but furthermore the 
precise setting of size, charge and composition are of high importance. 
Several reviews, dealing with BBB-targeted DDS, state a particle diameter of less than 100 nm 
as ideal [1, 5, 6]. Such values are not only a matter of target tissue-specific requirements but 
can also result from the uptake mechanism. In the case of a clathrin-mediated endocytosis, the 
size of DDS is restricted to the size of vesicles, which are formed during the clathrin-mediated 
endocytosis, enabling entry into the cell. These vesicles have a diameter of 100-150 nm [7, 8]. 
In addition to that Sonavane et al. showed size-dependent uptake into the brain of different 
sized gold nanoparticles after intravenous administration. In this study, the uptake of 15 nm 
gold nanoparticles was 500 times higher than the uptake of 100 nm gold nanoparticles [9]. 
Furthermore, the uptake of DDS is affected by the cell membrane surface, which is negatively 
charged due to heparan sulphate proteoglycans [10, 11]. Therefore, the uptake of positively 
charged DDS is commonly facilitated probably due to ionic interaction between cell and 
nanoparticle membrane (adsorptive-mediated uptake) [11]. 
In addition, PEGylation of DDS plays an important role in the uptake into target cells. DDS are 
normally PEGylated to reduce opsonisation and the uptake by the reticuloendothelial system 
(RES), resulting in a prolonged blood circulation time [12]. In case of active targeting strategies, 
PEG-chains can be used for the functionalization of DDS with brain specific ligands that enable 
receptor-mediated transcytosis.  
Liposomes are well suitable for BBB targeting strategies. As their physical (size, surface 
charge) and chemical characteristics (bilayer composition, degree of pegylation, bilayer 
rigidity) can be varied over a wide selection of lipids and preparation methods [13-15]. 
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This allows to address questions such as which characteristics do liposomes need to be taken 
up into the brain and how are we obtain these characteristics? 
Therefore, we wanted to establish a liposome formulation platform, which enables the setting 
of size, charge and target specific compositions to maximize BBB targeted uptake.  
 
2. Materials and methods 
 
2.1. Material 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-
2000] (DSPE-PEG-2000) were purchased from Lipoid GmbH (Ludwigshafen, Germany). 
Cholesterol (CHO), Docosahexaenoic acid (DHA) and Dulbecco´s phosphate buffered saline 
(PBS) (D1408) were obtained from Sigma-Aldrich (St. Louis, USA). R-DOTAP was obtained 
as chloride salt from Merck & Cie, Schaffhausen, Switzerland. Slide-A-LyzerTM Dialysis 
Cassettes (10kDa) were purchased from Thermo Fisher SCIENTIFIC Inc. (Waltham, USA). 
Ethanol was obtained from Merck KGaA (Darmstadt, Germany). Purified water was produced 
by a Millipore-Milli-Q integral water purification system (Merck KGaA, Darmstadt, Germany). 
 
2.2. Solvent-injection method 
 
Figure 1: Illustration of the solvent injection method. The lipids and CHO were dissolved in ethanol (step 1). The ethanol 
solution was injected into phosphate buffered saline (pH 7.0 - 7.5) (step 2). The dilution of the ethanol led to the formation of 
liposomes (step 3). The sample was dialyzed against PBS (pH 7.0 - 7.5) with a 10.000 MWCO slide-a-lyzer over 5 h and three 
buffer changes (step 4, 5).
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Liposomes were prepared using the solvent injection method [14]. The lipids and CHO were 
dissolved in ethanol (step 1). The ethanol solution was injected at a flow rate of 12 ml/min into 
PBS (pH 7.0 - 7.5) with a flow of 80 ml/min (step 2). The dilution of the ethanol led to a 
controlled precipitation of the lipids at the injection site, which were subsequently rearranged 
to form liposomes (step 3) [13, 14]. The size of liposomes was set by the initial total lipid 
concentration. Table 1 depicts the setting of initial and resultant final lipid concentration in 
dependency of the lipid- and buffer flow rate. The sample was dialyzed against PBS (pH 7.0 - 
7.5) with a 10.000 MWCO slide-a-lyzer over 5 h and three buffer changes (step 4, 5). The final 
TLC was set to 10 mM. Step 5 represents the final formulation, which was analyzed by dynamic 
light scattering (DLS) and laser diffraction electrophoresis (LDE).  
Table 1 shows the setting of final total concentration with a buffer to lipid flow ratio of 80 : 12 with increasing total lipid 
concentration (TLC). 
Initial TLC [mM] Flow rate: Buffer solution 
[ml/min] 
Flow rate: Lipid solution 
[ml/min] 
TLC [mM] 
19.2 
80 12 
2.5 
38.3 5 
57.5 7.5 
76.7       10 
153.3 20 
 
2.3. Size and zeta potential determination 
Size distribution and zeta potential (ZP) were determined by dynamic light scattering (DLS) 
and Laser Doppler electrophoresis (LDE) using a Zetasizer Nano ZS Malvern Instruments 
(Worcestershire, UK), equipped with a helium neon laser (λ=633 nm). For size distribution 
analysis samples were measured undiluted at 25 ± 0.1°C with fixed position (4.65 nm) at a 
detection angle of 173° (back scatter). Data was analyzed via cumulants fit. For the 
determination of ZP, samples were diluted tenfold with Milli-Q-water and measured at 25°C. 
ZP was calculated by Smoluchowski’s equation from the electrophoretic mobility of liposomes. 
All measurements were performed in triplicate. 
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3. Results and discussion  
The main objective of the presented work was the formulation of BBB specific liposomes. 
While doing so, the ranges for the key parameters size, charge, PEGylation and composition of 
liposome were defined according to biological conditions of the BBB. Key parameters have 
been set by selection of phospholipid, total lipid concentration (TLC) and preparation method. 
Liposomes were analyzed by DLS and LDE.  
 
3.1. Size 
The aim was to cover a broad size range from 20–150 nm to analyze size-dependency of 
liposomes. The size of liposomes is highly dependent on selection of liposome composition 
[16] and preparation method [13]. As liposome composition, a mixture of DOPC or DMPC, 
CHO and DSPE-PEG-2000 in molar ratio of 60:35:5 was chosen. DOPC was selected due to 
its ability to form flexible liposomes [17, 18]. This natural phospholipid, is composed of 
unsaturated fatty acids and has a low transition temperature. In contrast DMPC was selected 
due to the length of fatty acid chain (C 14), resulting as well in a low transition temperature. In 
contrast to DOPC, it is a synthetic lipid with saturated fatty acids[18]. Cholesterol is used as 
stabilizer in liposome compositions and has a strong influence on liposome bilayer properties 
by interacting with fatty acid chains [19]. The incorporation of the PEGylated lipid DSPE-PEG-
2000 ensured prolonged blood circulation time by reduced recognition of RES [12].  
The second fact influencing the size of liposomes is the preparation method. Liposomes within 
this size range are usually unilamellar vesicles and depending on their size further classified as 
small unilamellar vesicles (SUV) with a size of <100 nm or large unilamellar vesicles (LUV) 
with a size of >100 nm [13]. These liposomes are composed of a single phospholipid bilayer 
[20]. Several methods have been described for the preparation of such liposomes [20, 21]. A 
major criterion of these methods is the generation of monodisperse populations. Unfortunately, 
most conventional preparation methods require additional homogenization to obtain 
monodispersed populations. This can be done by extrusion through a filter with defined pore 
size [22] or sonication [23]. In contrast liposomes with narrow size distribution can be obtained 
by injecting alcoholic lipid solution into the excess buffer [14]. In addition, this method allows 
the adjustment of defined size ranges by adjusting the lipid to buffer ratio [24] These facts 
highly motivated us to select this method.
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Figure 2: Physicochemical characterization of liposomes, before (BP) and after their purification (AP) composed of 
DMPC or DOPC, CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5.The liposomes were prepared by the solvent 
injection method to a total final lipid concentration of 10 mM. (Mean ± SD of three individual batches, n=3). 
 
Figure 2 depicts results of physicochemical characterization of both formulation composed of 
either DMPC or DOPC, CHO and DSPE-PEG-2000 in molar ratio of 60:35:5. Final TLC of 10 
mM was defined according to common liposome preparation procedures [20]. DOPC liposomes 
had a size of 140 ± 1 nm (PDI: <0.25) before purification, which decreased thereafter to 102 ± 
2 nm (PDI: <0.25). DMPC liposomes had a size of 164 ± 4 nm (PDI: <0.2) before purification, 
which decreased to 114 ± 2 nm (PDI: <0.2). The decrease in size can be explained by the 
removal of the ethanol. Ethanol interacts with phospholipid membranes [25], therefore, removal 
results in a reorganization of phospholipid membrane and causes a change in size. We were 
able to prepare SUV with both formulations. With a size of around 100 nm, both formulations 
provided liposomes at the upper size limit. Yet, both formulations were further analyzed with 
respect to size variation. Therefore, liposomes were prepared by increasing the initial TLC from 
38.3 to 153.3 mM and a constant flow of buffer and lipid solution.  
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Figure 3: Physicochemical characterization of liposomes after purification, composed of DMPC or DOPC, CHO and 
DSPE-PEG-2000 in a molar ratio of 60:35:5 with increasing TLC. The liposomes were prepared by the solvent injection 
method to a total final lipid concentration of 10 mM. (Mean ± SD, n=3). 
 
Figure 3 depicts the results of size titration of DOPC and DMPC liposomes. DOPC liposomes 
showed a size increase depending on the initial TLC from 46 ± 5 nm to 405 ± 10 nm. In contrast, 
the size of DMPC liposomes was not affected by increasing TLC and was approximately 130 
nm. DOPC liposomes were much more sensitive to increasing TLC, resulting in a size increase, 
which was accompanied by an increase in PDI. In contrast, the size of DMPC liposomes was 
not affected by increasing TLC, resulting in a PDI decrease. These results could be explained 
by chemical properties of both phospholipids. DOPC is a natural, unsaturated phospholipid, 
which is much more flexible compared to the rigid structure of DMPC, which has saturated 
fatty acids [18]. The stability of DOPC formulations was proven over a time period of 4 weeks. 
Liposomes were stored at 2 - 8°C. No changes in size were observed (Figure 4). 
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Figure 4: Stability of liposomes composed of DOPC, CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5 
with increasing TLC. Liposomes were stored at 2 - 8°C over a time period of 4 weeks Mean ± SD, n=3). 
 
A further assessment of size titration is depicted in Figure 5. Size of DOPC increased depending 
on the TLC concentration in organic lipid stock, within the concentration range of 19.3 to 153.3 
mM. The linear relationship between the TLC and size was shown for the concentration range 
of 5 to 10 mM, whereas the lowest and highest TLCs resulted in sizes which were not linear to 
concentration. Although the target size range of 20 – 150 nm could not completely be covered, 
these results verified that DOPC formulations are well suitable for the analysis of size 
dependent uptake in brain delivery in contrast to DMPC formulation.  
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Figure 5: Physicochemical characterization of liposomes after dialysis prepared by the solvent injection 
method with an increasing TLC, starting from 2.5 mM up to 20 mM. The formulation was composed of 
DOPC, CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5. (Mean ± SD, n=3). 
 
3.2. Positively charged liposomes 
Positive charge can be set by the modification of DDS with so-called cell-penetrating peptides 
(CPP), which consist of positively charged amino acids like arginine [26-28]. Another approach 
is the use of positively charged lipids like R-DOTAP. This lipid is normally applied as a 
transfection agent in gene delivery. The positive head group of lipid enables the interaction with 
DNA, forming stable lipoplexes [29]. For our platform DOTAP was chosen for the preparation 
of positively charged liposomes. By incorporation of DOTAP in liposome composition, the 
surface charge changes to positive values and, therefore, enables the electrostatic interaction of 
liposomes with a negatively charged cell membrane. The liposomes composed of DMPC, CHO 
and DOTAP in a molar ratio of 50:30:20 with a final TLC of 10 mM had a size of 183 ± 15 nm 
(PDI < 0.3) before dialysis and 152 ± 5 nm (PDI <0.37) after dialysis with a positive charge of 
+ 20 ± 4 mV. Size and charge were in an acceptable range and met the desired criteria for the 
assessment of the uptake in brain endothelial cells with respect to adsorptive-mediated uptake 
[11]. The incorporation of DOTAP into the DMPC liposome formulation led to an increase in 
size and PDI. Figure 6 depicts the physicochemical characterization of positively charged 
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liposomes in comparison to DOPC and DMPC liposomes prepared by the solvent injection 
method. Such changes in physicochemical properties could be caused by the interactions of 
DOTAP with DMPC in the bilayer membrane and electrostatic interactions with the used buffer 
media. Campbell et al. showed that the physicochemical properties of PC-containing liposomes 
were impacted by increasing the amount of DOTAP. However, in contrast to our results, the 
incorporation of DOTAP into PC-liposomes resulted in a decrease in size with increasing 
amount of DOTAP [30].  
 
Figure 6: Physicochemical characterization of positively charged liposomes in comparison to DOPC and DMPC 
liposomes prepared by the solvent injection method. The DOTAP-formulation was composed of DMPC, CHO and 
DOTAP in a molar ratio of 50:30:20 with a final TLC of 10 mM. The DOPC and DMPC formulation were 
composed of DMPC or DOPC, CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5 with a final TLC of 10 mM. 
(Mean ± SD, n=3). 
 
3.3. PEG incorporation into liposomes 
PEGylated lipids with functional groups bring two characteristics to the DDS. First, the 
PEGylation of liposomes enables a prolonged circulation lifetime due to reduced recognition 
by macrophages. Second, a functional group at the end of the PEG chain enables the attachment 
of specific ligands. A decisive factor for the uptake into the brain is the amount of PEG 
incorporated into the liposomes. While the amount of attached ligand might be highly 
dependent on the ligand and receptor of choice, it should be taken into account that a higher 
amount of PEG molecules on the DDS results, on the one hand, in reduced recognition by 
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macrophages, but also might affect the recognition of target cells [31]. The production of 
liposome with varying amounts of PEG are therefore, of utmost interest. DSPE-PEG-2000 was 
used as a model compound for the assessment of PEG incorporation. Figure 7 depicts the results 
of DSPE-PEG-2000 titration in a DOPC CHO liposome formulation, starting with 1 mol% up 
to 20 mol%. The formulations with 5 and 10 mol% showed the best results with regard to size 
and PDI. Overall size decreased with increasing PEG amount. After an increase of 10 mol%, 
DLS measurements are characterized by a decrease in size and an increase of PDI, indicating 
the disruption of lipid bilayer and formation of micelles [32, 33]. With increasing amount of 
PEG-lipids, PEG moieties concentrate on the surface of the liposome. While at lower PEG-
lipid amounts the PEG moieties exist in a so-called mushroom regime, the increase in the PEG 
amount in the lipid bilayer causes a switch to the brush regime. The PEG moieties are now able 
to interact with each other on the surface of the lipid bilayer. This interaction causes the 
disruption of the lipid bilayer, resulting in the formation of micelles [32]. The results indicated 
an amount of 5 and 10 mol% of DSPE-PEG-2000 as feasible for the formulation composed of 
DOPC, CHO and DSPE-PEG-2000. The results could be also transferred to the formulation of 
liposomes containing DSPE-PEG-2000-Mal instead of DSPE-PEG-2000. The data with an 
amount of 5 mol% DSPE-PEG-2000-Mal is shown in chapter 3.  
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Figure 7: Physiochemical characterization of liposomes with increasing PEG-concentration starting from 
1% up to 20% after dialysis (AD) prepared by the solvent injection method. The formulation is composed 
of DOPC, CHO and DSPE-PEG-2000 (Mean ± SD, n=3), *n=1. 
 
3.4. Preparation of DHA-incorporated liposomes 
Besides the size, charge and PEG-amount of a DDS, the composition might also have a decisive 
impact on the uptake into the brain. A frequently followed idea is to incorporate nutrients for 
the brain tissue into the liposome. The lipid bilayer structure of liposome enables the 
incorporation of brain specific lipophilic nutrients. DHA is an omega-3 fatty acid, which is 
important for brain development and function [34]. As DHA cannot be synthesized in the brain, 
the uptake is regulated by transporters into the brain. The Mfsd2, a member of the major 
facilitator superfamily, was recently identified as a DHA transporter, enabling transport across 
the BBB [35]. Using the neuroprotective effect of DHA, Eckert et al. formulated DHA-
incorporated liposomes for the therapy of Alzheimer´s disease (AD) [36]. Therefore, DHA 
could not only be used as a neuroprotectant but, also facilitates the uptake of formulations by 
interacting with DHA receptors. Figure 8 depicts the results of the incorporation of DHA into 
liposomes. According to the liposome preparation by the solvent-injection, DHA was directly 
added to the alcoholic solution in a molar ratio of 50:33:17 (DOPC CHO:DHA). 0.05% 3,5-Di-
tert-4-butylhydroxytoluene (BHT) was added as an antioxidant.  
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The liposomes had a size of 77 ± 5 nm with a PDI of <0.2 and a charge of -25 ± 3 mV before 
purification. The purification process did not influence size and charge characteristics (74 ± 2 
nm with a PDI of <0.25 and charge of -25 ± 4 mV). With a size of <100 nm the liposomes are 
well suitable for the uptake into cells according to literature [8]. The increase of negative charge 
compared to the surface charge of PC liposomes can be explained by the incorporation of the 
DHA with a free carboxyl group.  
 
Figure 8: Physiochemical characterization of DHA-incorporated liposomes composed of DOPC, CHO and DHA 
with a molar ratio of 50:33:17, before (BP) and after purification (AP) prepared by the solvent injection method 
with a TLC of 10 mM. (Mean ± SD, n=3).  
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4. Conclusion 
The presented work suggests important ways for the design of liposomes optimized for BBB 
targeting. Beside active targeting strategies, decisive factors like size, charge, PEG amount and 
brain-specific lipids were taken into account. Hence, the presented liposome formulations can 
be seen as screening platform for the decision of BBB targeted liposomes. The results underline 
the complexity and hence the necessity of careful parameter tuning in liposome formulation 
development. 
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Abstract
Functionalized phospholipids are indispensable materials for the design of targeted liposomes.
Control over the quality and quantity of phospholipids is thereby key in the successful
development and manufacture of such formulations. This was also the case for a complex
liposomal preparation composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC),
Cholesterol (CHO), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol)-2000] (ammonium salt) (DSPE-PEG-2000). To this end, an RP-HPLC method was
developed. Detection was done via evaporative light scattering (ELS) for liposomal
components. The method was validated for linearity, precision, accuracy, sensitivity and
robustness. The liposomal compounds had a non-linear quadratic response in the concentration
range of 0.012-0.42 mg/ml with a correlation coefficient greater than 0.99 with an accuracy of
method confirmed with 95-105% of the theoretical concentration. Furthermore, degradation
products from the liposomal formulation could be identified. The presented method was
successfully implemented as a control tool during the preparation of functionalized liposomes.
It underlined the benefit of HPLC analysis of phospholipids during liposome preparation as an
easy and rapid control method for the functionalized lipid at each concentration step as well as
for the quantification of all components.
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1. Introduction
The analytical characterization is a sine qua non for the development of liposomes. While size
distribution, surface charge and drug encapsulation efficiency are commonly determined for
liposomal preparations, the quantification of phospholipids (PL) is often missing when it comes
to their characterization. The PL content is usually assessed by analyzing the organic
phosphates groups using the Barlett assay or via enzymatic reactions [1]. A significant
disadvantage of these methods is that only a total lipid content is obtained rather than the
specific composition of individual components. In addition, nowadays designed liposomes are
often composed of functionalized lipids, such as PEGylated materials containing polyethylene
glycol chains that are intended to support escape from the reticuloendothelial system [2]. These
functional lipids could also provide functional groups that enable the coupling of targeting
ligands [3, 4], the labeling with fluorescent dyes or the use in diagnostic applications [5-7].
DSPE-PEG-2000-Maleimide (DSPE-PEG-2000-Mal) is such a functionalized lipid, which
combines the advantages of PEGylation with the possibility of coupling a ligand of choice for
selective receptor binding. The use of a maleimide functionalized lipids is part of the classical
ligation strategies. In the presence of thiol-reactive ligands stable thioether bonds are formed at
the end of PEG-chain [8, 9]. Especially peptides are well suited for the maleimide-thiol
coupling, as their sequence can be easily modified by the addition of cysteines or the creation
of thiols by the use of chemical reagents, like N-succinimidyl S-acetylthioacetate (SATA) [10].
In the present work, a 29 amino acid glycopeptide (RVG-29) derived from rabies virus served
as a model ligand. RVG-29 consists of the bioactive part of the glycoprotein relevant for cellular
uptake of the whole virus into the CNS [11]. The peptide was modified with an additional
cysteine on the C-terminal end to enable the coupling reaction to the DSPE-PEG-2000-Mal.
Since it was our intention to control the amount of thiol-reactive lipid, there was an urgent need
for a suitable analytical method, which allowed quantitative analysis of all individual liposome
components during manufacturing. To our surprise the question of the quantification of such
functionalized lipids is not raised. The principle of liquid chromatography offers as analytical
method for the quantification of liposomes as it is well described for the analysis of
phospholipids. The principal goal was to develop and implement a HPLC method for the
manufacturing process of a liposomal formulation composed of DOPC, CHO and DSPE-PEG-
2000 to control critical steps of preparation regarding loss of lipid or the formation of
degradation products.
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2. Materials and methods
2.1. Materials
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000]
(ammonium salt) (DSPE-PEG-2000) and Lysophosphatidylcholine (Lipoid E LPC RS) were
purchased from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol and DPBS10x (D1408)
were obtained from Sigma-Aldrich (St. Louis, USA). 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (ammonium salt) (DSPE-
PEG(2000) Maleimide) (DSPE-PEG-2000-Mal) was purchased from Avanti Polar Lipids
(Alabaster, USA). The peptide RVG, derived from rabies virus, with an additional cysteine on
the C-terminus (YTIWMPENPRPGTPCDIFTNSRGKRASNGC) was synthesized by Merck.
Float-a-lyzer G2 (50kDa) were purchased from SPECTRUM® LABORATORIES Inc.
(Rancho Dominguez, USA). Methanol, isopropanol, both HPLC grade, and ethanol and
ammonium acetate were obtained from Merck KGaA (Darmstadt, Germany). Purified water
was produced by a Millipore-Milli-Q integral water purification system (Merck KGaA,
Darmstadt, Germany).
2.2. Methods
2.2.1 HPLC analysis
HPLC analysis was done using an Agilent 1260 Infinity (Agilent Technologies, Santa Clara,
USA), equipped with a binary pump, mobile phase degasser, temperature-controlled
autosampler, column thermostat, UV and evaporative light scattering detector (1260 ELSD).
For separation a Kinetex Column (C18, 2.6u, 100Å, 100x3 mm) was used from Phenomenex
(Torrance, Canada). The chromatograms were analyzed by EZ Chrom Elite Chromatography
Data Systems Version 3.3.2. 1037 SP2 (Agilent technologies, Santa Clara, USA).
Eluent A was composed of methanol and water in a volume ratio of 40:60 with 10 mM
ammonium acetate with a pH-value of 6.4, which was adjusted with 1 mM acetic acid. Eluent
B was composed of methanol and isopropanol in a ratio of 10:90 with 10 mM ammonium
acetate. The autosampler temperature was set to 20°C, the temperature of the column was set
to 25°C. Temperature of evaporator and nebulizer was set to 55°C and 45°C with a gas flow of
1.50 standard liter per minute (slm) operated with 10.06 Hz. Stop run of sequence was after 20
min with a flow of 0.6 ml/min and an injection volume of 8 µl. The method was gradient based,
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starting with first gradient phase from 0-2.6 min from 100% A to 20% A, followed by an
isocratic phase from 2.6-5.3 min with 20% A and a second gradient phase from 5.3-10.6 min to
0% A, and followed by a second isocratic phase from 10.6-13.3 min (see Table 1). After that
the column was flushed back to initial conditions.
Prior to HPLC analysis, the liposomal formulations were diluted with isopropanol according to
the concentration range of calibration. Method validation included specificity, linearity,
precision, accuracy, sensitivity and robustness. For specificity of method, a sample containing
DOPC, CHO and DSPE-PEG-2000 was directly diluted with a isopropanol-water mixture in
the ratio 9:1 and compared with respect to retention time and a resolution factor >2. A sample
with known concentration, containing all three components, was diluted to at least 5 different
concentrations to cover the entire working range. Each dilution was injected twice. The
averaged peak area was plotted against the concentration. The correlation coefficient should be
greater than 0.99. Recovery was tested at two different concentrations, the deviation should be
less than +/- 5%. Furthermore, a liposomal formulation was diluted with isopropanol and
injected six times on different days. The relative standard deviation of retention time, peak area
of each compound as well as the total peak area should be smaller than 3%. The detection limit
was visually determined by the analysis of samples with known concentrations of analyte and
by establishing the minimum level at which the analyte can be reliably detected. For
differentiation of degradation products, a liposomal formulation was exposed to 0.1N NaOH,
0.1N HCl, 3% H2O2 and at 50°C for 24 h.
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Table 1: Conditions of HPLC method for the analysis of a liposomal formulation composed of DSPE-PEG-2000 (1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-(aminopolyethylene glycol)-2000), CHO (Cholesterol), and DOPC (1,2-
dioleoyl-sn-glycero-3-phosphocholine detected via ELS.
MeOH (methanol), IPA (isopropanol), H2O (water), NH4+OAc- (ammonium acetate).
Solvent
Solvent A: MeOH/H2O (40/60),10 mM NH4+OAc-, 1 mM Acetic acid
(yields pH 6.4)
Solvent B: IPA/MeOH (90/10), 10 mM NH4+OAc-, 1 mM Acetic acid
Column heater [°C] 25
Flow [ml/min] 0.6
Column Kinetex 2,6u C18 100A
Injection volume [µl] 8
Stop time [min] 20
Detector ELS and UV
ELSD - Evaporator Temperature
[°C] 55
ELSD - Nebulizer [°C] 45
UV [nm] 220
Compound DSPE-PEG-2000 CHO DOPC
Liposome concentration [mg/ml] 1,41 1,36 4,74
Diluent IPA
2.2.2 Preparation via ethanol injection method
The phospholipids and cholesterol were diluted in ethanol with a total lipid concentration of 77
mM. PBS was used as the aqueous phase. The ethanolic solution was injected with a flow rate
of 12 ml/min into DPBS with a flow of 80 ml/min to afford a total lipid concentration of 10
mM. Purification of ethanol was done by dialysis over 5 h and three buffer changes. For the
preparation of targeted liposomes, DSPE-PEG-2000-Mal was used instead of DSPE-PEG-
2000.
2.2.3 Preparation via lipid-film-hydration
The phospholipids and cholesterol were diluted in dichloromethane with a total lipid
concentration of 10 mM. The lipid-film was generated by rotary evaporation. Organic solvent
was removed under vacuum overnight. The film was hydrated in DPBS for 1 h at 60°C. Sizing
was performed by extrusion through a 200 nm-sized polycarbonate membrane, followed by a
100 nm sized-polycarbonate membrane with 21 extrusion steps per preparation.
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2.2.4 Preparation of targeted liposomes
For the preparation of targeted liposomes DSPE-PEG-2000-Mal was used instead of DSPE-
PEG-2000 (see above). In the present work, the rabies virus glycopeptide with 29 amino acid
residues (RVG-29) derived from the rabies virus served as a model ligand [11]. Liposomes
were reacted with RVG-29 in a molar ratio of 1:2 (1 µmol RVG per 0.544 µmol DSPE-PEG-
2000-Mal) for 1 h at room temperature under inert conditions at a pH of 7.0. To remove
unbound targeting ligand, liposomes were dialyzed overnight at 4°C with three buffer changes.
2.2.5 Statistical analysis
All values are expressed as means ± standard deviation (SD). Statistical data analyses were
performed using the Student's t-test with p < 0.001 as level of significance. All tests were
performed using the statistical software SigmaPlot (Systat Software, San Jose, CA).
3. Results and discussion
The implementation of HPLC analysis as a control tool during the preparation of functionalized
liposomes was defined as our principal goal. Therefore, the work was divided into the
development and validation of the method and the analytical application as proof of concept.
HPLC method development, optimization and validation
The physicochemical properties of PL, in particular of pegylated types, are challenging to
characterize via HPLC analysis. Since they show poor UV absorption sensitivity, the analysis
is limited to special detection methods [12]. Modification of PEG-chains with aromatic reagents
is one method to overcome this problem. The use of detection methods that are independent of
optical properties, like ELS is a common approach in the analysis of phospholipids. The ELS
detects non-volatile particles by means of the scattered light [13, 14]. In contrast to UV
detection, ELS detection is mass-dependent and not concentration-dependent [14].
Quantification is challenging due to the non-linearity of the response over a wide concentration
range, the response variation with the composition of mobile phase, and the detector sensitivity
[15, 16]. However, an advantage of ELS detection in the analysis of phospholipids is its greater
sensitivity in comparison to UV detection. This leads to a reduction of concentration working
range down to 0.1 mg/ml.
The use of ELS detection for the quantification of liposomal components was only described
by a few groups [17, 18]. Thereof the work of Shibata et al. is the only one that describes a
method for the determination of PEGylated lipids in a liposomal formulation. By using the lipid
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composition of the liposome formulation of Doxil®, they were mainly interested in the
detection of temperature induced degradation products via HPLC.
The simultaneous detection of DSPE-PEG-2000, CHO and DOPC was feasible with the
described method. The optimal separation was achieved at a column temperature of 25°C and
a flow rate of 0.6 ml/min. A further increase of column temperature led to a fusion of the peaks
of CHO and DOPC.
Figure 1: HPLC analysis of a liposomal formulation composed of DSPE-PEG-2000 (Rt= 5.2 min), CHO (Rt= 5.8 min)) and
DOPC . The liposome formulation was diluted with isopropanol (IPA) prior to HPLC analysis. The injected amount was 1.1
µg for DSPE-PEG-2000, 1 µg for CHO, and 3,7 µg for DOPC (baseline subtracted).
Figure 1 depicts a typical chromatogram. All three liposomal compounds could be detected in
the following order DSPE-PEG-2000 (RT= 5.2 min), CHO (RT= 5.8 min) and DOPC (RT= 6.1
min); peaks were not completely baseline separated according to ICH (International Conference
on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human
Use) guidelines by a resolution factor of >2. The resolution factor between DSPE-PEG-2000
and CHO was 1.8 in contrast to that the resolution factor of 1.1 between CHO and DOPC, which
indicated an incomplete baseline separation. Further optimization of flow rate was limited due
to high backpressure, therefore the method validation was executed with the above mentioned
settings. The linearity was tested in the following calibration ranges for 0.042-0.42 mg/ml for
DSPE-PEG-2000, 0.012-0.12 mg/ml for CHO, and 0.03-0.31 mg/ml for DOPC (Table 2).
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Table 2: Quantification was done via ESTD-calibration. The linearity was tested in the following calibration range: DSPE-PEG-2000 (0.042-
0.42 mg/ml), CHO (0.012-0.1 mg/ml), and DOPC (0.03-0.3 mg/ml). In this concentration range, the ELSD response followed a non-linear
quadratic relationship, indicated by a correlation coefficient greater than 0.99 for all three components. (Mean ± SD, n=3).
DSPE-PEG-2000 CHO DOPC
Calibration
range
[mg/ml]
0.042-0.42 0.012-0.12 0.03-0.31
y=ax2+bx+c r2 (±σ) 0.996 (± 0.002) 0.990 (± 0.005) 0.996 (± 0.001)
In this concentration range, the ELS detection response followed a non-linear quadratic
relationship that had a correlation coefficient greater than 0.99 for all three components [19].
Each concentration was analyzed in triplicate. The recovery of the method was tested with
samples with known concentration and should be within a deviation of 95-105% of the
theoretical concentration (Table 3).
Table 3: A positive control consisting of DSPE-PEG-2000 , CHO and DOPC diluted in a mixture of water: isopropanol in a
ratio of 10:90 with known concentration, was injected at two different concentrations. The deviation should be less than +/-
5%.
Compound Theoretical concentration
[mg/ml]
Measured concentration
[mg/ml]
Recovery
[%]
DSPE-PEG-2000 0.314 0.327 104.1
0.262 0.271 103.4
CHO 0.077 0.076 98.7
0.039 0.038 97.4
DOPC 0.270 0.280 103.7
0.135 0.132 97.7
The percentage residual standard deviation of the retention time, peak area of each compound
as well as the total area was less than 3% for two liposomal formulations both composed of
DSPE-PEG-2000, CHO, and DOPC (Table 4).
Table 4: Precision: A sample was injected six times on different days. The % relative standard deviation of retention time, peak
area of each compound as well as the total peak area should be smaller than 3%.
DSPE-PEG-2000 CHO DOPC
Sample 1
% 
rel
ati
ve 
sta
nd
ard
dev
iat
ion
Rt 0.33 0.26 0.25
Peak area 0.8 2.24 0.7
Total Peak area 1.22
Sample 2
Rt 0.101 0.088 0.082
Peak area 0.376 1.044 0.314
Total Peak area 0.482
With regard to the non-linearity of the ELS detection response the LOD was determined
visually: 144 ng for DSPE-PEG-2000, 56 ng for CHO, and 120 ng for DOPC. For the analysis
of degradation products, aliquots of the placebo liposome formulation were each exposed to
0.1N NaOH, 0.1N HCl, 3% H2O2, or 50°C. The fact that HPLC analysis enabled the detection
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of phospholipid degradation products showed the versatility of this analytical method.
Phospholipids tend to degrade over time due to hydrolysis or oxidation. Both degradation
pathways can be induced by oxygen, pH-shift, or increased temperature. Lysophospholipids
and free fatty acids are generated. The hydrolysis of phospholipids was pH- and temperature-
dependent. The pH-dependence was “V-shaped” with a minimum at a pH of 6.5. The effect of
temperature can be described by the Arrhenius equation. In aqueous dispersions at a storage
temperature of 4°C, the lyso-lipid formation is >20% per month [20]. For the used liposomal
formulation expected degradation products of the phospholipids were free fatty acids like oleic
and stearic acid, lyso-forms of DOPC and DSPE-PEG-2000 as well as glycerophospho-
compounds. Lysophosphatidylcholin (Lyso-PC) as the main degradation product of liposomal
formulations causes destabilization of the lipid bilayer due to enhanced permeability [17].
Besides active degradation induced by exposure to the aforementioned substances, a Lyso-PC
standard could also be detected by the described method (Figure 2).
Figure 2: The chromatogram shows the detection of the Lysophosphatidylcholin (Lyso-PC) standard (solid line) in comparison
to a normal liposomal formulation (dotted line) (Baseline subtracted).
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The exposure of a liposomal formulation composed of DSPE-PEG-2000, CHO, and DOPC to
0.1N NaOH or 0.1N HCl induced a hydrolysis for both phospholipids. The exposure to 0.1N
NaOH led to a complete hydrolysis of DOPC and DSPE-PEG-2000. In the HCl-stressed sample
DOPC was still detectable, in addition to a new peak that appeared, which was not further
analyzed. In contrast to that the exposure to 3% H2O2 or 50°C did not induce further degradation
products within the time period of 24 h (Figure 3). A further differentiation of the degradation
products was not analyzed.
Figure 3: Liposomal formulations composed of DSPE-PEG-2000, CHO and DOPC (solid line) were exposed to 0.1N NaOH ,
0.1N HCl , 3% H2O2, and 50°C (data not shown) for 24 h and compared with a non-stressed sample . The exposure to 0.1N
NaOH led to a complete hydrolysis of DSPE-PEG-2000 and DOPC. The exposure to 0.1N HCl showed a new unknown peak,
but DSPE-PEG-2000 and DOPC were not completely hydrolyzed to their lysoforms. Neither the exposure to with 3% H2O2
nor the exposure to 50°C for 24 h showed any degradation products.
Application to a liposomal preparation with surface immobilized peptide
The preparation of so called targeted formulations was a multistep process. These multi-step
processes required control on the concentrations of desired functionalized PEG lipid and the
ligand immobilized to it over the sequence of operations. In the ethanol injection method, a
phospholipid solution was injected into a perpendicularly flowing aqueous phase applied by a
T-shaped stainless steel device with defined geometry. The dilution of the ethanol led to a
controlled precipitation of the lipids at the injection site, which subsequently rearranged to form
liposomes [21, 22]. The removal of ethanol followed directly after the preparation and was
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performed mostly by dialysis. Critical steps of lipid loss could be due to adsorption effects on
material surfaces during the ethanol injection step. In addition to that the dialysis process might
especially change the concentration of a component. Either due to adsorption to the dialysis
membrane, by simple removal of lipids, which were not completely incorporated into the lipid
bilayer, or due to dilution effects. To control these preparation steps, different placebo
formulations were screened regarding the retention of the PEGylated component during the
whole preparation process.
Figure 4: The graph showed the concentration of DSPE-PEG-2000 in three different liposomal placebo formulations after
dialysis, which were performed with a cutoff of 50 kDa and three buffer changes over a time period of 5 hours. All
formulations were composed of the main phospholipid or phospholipid mixture DMPC , DOPC or DOPC and DOPE,
cholesterol, and the PEGylated lipid (DSPE-PEG-2000) with the molar ratio of 60:35:5 for the DMPC and DOPC
liposomes and with a molar ratio of 30:30:35:5 for the phospholipid mixture of DOPC and DOPE.
(Mean ± standard deviation (SD), n=3).
Figure 4 displays the measured concentration of the DSPE-PEG-2000 after dialysis. The
formulation composed of DOPC, CHO, and DSPE-PEG-2000 could maintain the initial content
of the PEGylated component over the purification process, whereas the two other formulations
showed a minimal loss of lipid. The formulation composed of DOPC as the main phospholipid
was chosen for further analysis. The described method was applied to two different preparation
processes for such targeted formulation. Besides the ethanol injection method, the lipid-film-
hydration was used as it is an approved method for the preparation of liposomes [23, 24].
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In both cases the formation of targeted liposomal formulations required additional steps
compared to the “regular” preparation procedure. The addition of ligand could lead to further
changes in lipid composition.
Figure 5 depicts the comparison of two preparation methods for targeted liposomal formulations, regarding the
amount of DSPE-PEG-2000-Mal in the final formulation of a liposome composed of DOPC, CHO and DSPE-PEG-
2000-Mal. Statistical data analyses were performed using the Student's t-test with p < 0.001 as level of significance.
(Mean ± SD, n=3), ns= not significant.
Figure 5 depicts the comparison of both preparation methods regarding the amount of DSPE-
PEG-2000-Mal in the final formulation of a liposome composed of DOPC, CHO and DSPE-
PEG-2000-Mal. In both formulations only an amount of 0.1 mM DSPE-PEG-2000-Mal could
be detected from an initial amount of 0.5 mM. The performed t-test indicated no statistically
significant difference in the results of the two preparation methods. In contrast the results of the
non-functionalized liposomes were different to the functionalized liposomes (p<0.001).
Surprisingly, the functionalized formulations could not maintain the initial concentration of
DSPE-PEG-2000-Mal. As both preparation methods yielded similar results, we hypothesized
that the dramatic loss of lipid could be due to the interaction of the targeting ligand with the
liposomal formulation. With the aid of this HPLC method different phospholipids and
preparation methods could be analyzed regarding their usage in the field of functionalized
liposomal formulations. The ligand density could be calculated with the actual amount of
functional lipid and was not based on theoretical considerations.
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4. Conclusion
The described method allowed direct tracking of all compounds during each step of liposome
preparation. It provided information about the actual composition of liposomes. Especially
during the purification as well as during the coupling of ligands, the individual loss of lipids
could change the composition of liposomes. With regard to functionalized lipids where the
concentration of lipid is important for further coupling reactions, the described method gave
evidence about the correct concentration. The loss of lipid during preparation could be due to a
variety of reasons. The method provided a qualitative statement of the actual amount in final
formulations and allowed a deeper insight into peptide-functionalized liposomes.
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Abstract
Numerous examples exist in the literature for the use of maleimide-thiol-reactions in the area
of functionalized nanoparticles. Although the hydrolysis tendency of maleimides is well-
known, qualitative and quantitative information on the stability and reactivity of maleimide
groups during preparation and in final formulations are missing. This is surprising, since
hydrolysis of maleimides prevents nanoparticle functionalization and results in an increase of
negative surface charge due to the hydrolysis product maleic acid. In this study we investigated
the stability of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide-2000] (DSPE-
PEG-2000-Mal) during the preparation of liposomes via two common preparation methods,
which can be distinguished by the insertion of DSPE-PEG-2000-Mal during or after the
liposome formation process (pre-insertion and post-insertion process). The liposomes prepared
by the pre-insertion method had 63% active maleimide groups remaining on their surface. The
activity decreased dramatically during the purification process down to 32%. The preparation
by post-insertion showed minimal effects with regard to maleimide activity. 76% of maleimide
groups were active and therefore available for coupling reaction. By identifying active
maleimide groups on the surface of the final formulations, the presented work revealed the
dramatic impact of preparation methods on the activity of maleimide groups.
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1. Introduction
The maleimide-thiol reaction gained great popularity in the field of surface modification of drug
delivery systems (DDS) [1, 2] and bioconjugation of drugs to antibodies [3]. Maleimides react
with thiols resulting in the formation of stable thioether bonds. The specificity to thiols, fast
aqueous reaction kinetics and mild reaction conditions explain their broad pharmaceutical
application in DDS functionalization [4, 5]. A great pitfall however is the pH-dependent
hydrolysis of maleimides, which is often neglected. With increasing pH (pH >8), maleimide
groups are hydrolyzed to maleic acid, a ring-open hydrolysis product that lacks an electrophile
carbon and is, therefore, unable to react with nucleophile thiols [4, 6-8]. This hydrolysis carries
two inherent risks for functionalized DDS, as the DDS does not obtain the desired
functionalization but furthermore, resulting in an increase of free carboxyl groups on the outer
surface. This fact becomes especially critical in active targeting strategies, where the
functionalization should enable a controlled and specific uptake into cells. The absence of
ligands and increase of negative charge on the outer surface can result in unspecific uptake
pattern of nanoparticles [9, 10]. Although the risk of the hydrolysis of final functionalized DDS
is intensively discussed in the literature, the impact of the preparation on maleimide activity is
completely overlooked [11, 12]. Facing the risk of maleimide hydrolysis during preparation,
the use of maleimide functionality for liposome functionalization is an interesting example. The
complex composition of liposomal formulations as well as the multi-step character of the
preparation are critical parameters with potential impact on the activity of maleimides. In that
regard, we had a closer look at two common functionalization methods for liposomes modified
with maleimide-containing PEGylated phospholipid 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide-2000] (DSPE-PEG-2000-Mal). We investigated the
maleimide acitivty of DSPE-PEG-2000-Mal during preparation of liposomes by solvent-
injection and their functionalization via pre-insertion or post-insertion. The distinct difference
feature between both methods is the insertion of DSPE-PEG-2000-Mal, which is either during
(pre-insertion) or after liposome formation (post-insertion) [13]. Both methods have potential
risks with respect to maleimide activity. Therefore, tracking maleimide activity during the
complex preparation processes was the main purpose of our studies.
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2. Material and methods
2.1. Material
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-2000]
(DSPE-PEG-2000) were purchased from Lipoid GmbH (Ludwigshafen, Germany). Cholesterol
(CHO), Ethylenediaminetetraacetic acid (EDTA) and Dulbecco´s phosphate buffered saline
(PBS) (D1408) were obtained from Sigma-Aldrich (St. Louis, USA). 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[maleimide-2000] (DSPE-PEG-2000-Mal) was purchased from
Avanti Polar Lipids (Alabaster, USA). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP)
was purchased from AMRESCO LLC (Solon, USA). Rabies virus glycopeptide (RVG) and
EPRNEEK peptide, both modified with terminal sulfhydryl-groups and supposed to enable
blood-brain barrier targeting, were used as model ligands (Kumar, Wu et al., 2007; Liu, He et
al., 2014). The peptides were modified with an additional cysteine on the C-terminus and were
synthesized by Novo Nordisk A/S (Bagsvaerd, Denmark). Float-a-lyzer G2 (50kDa) was
purchased from SPECTRUM® LABORATORIES Inc. (Rancho Dominguez, USA). Methanol,
isopropanol (HPLC grade), ethanol, dichloromethane, ammonium acetate, L-cysteine,
disodium hydrogen phosphate, sodium dihydrogen phosphate and 2,2´Dinitro-5,5´-dithio-
dibenzoic acid (DTNB), also referred to as Ellman´s reagent, were obtained from Merck KGaA
(Darmstadt, Germany). Purified water was produced by a Millipore-Milli-Q integral water
purification system (Merck KGaA, Darmstadt, Germany).
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2.2. Methods
2.2.1 Preparation of functionalized liposomes by pre-insertion method
The preparation of ligand-functionalized liposomal formulations was a multistep process
(Figure 1, Table 1). Liposomes were prepared using a solvent injection method [14]. DSPE-
PEG-2000-Mal, DMPC and CHO were diluted in ethanol with a total lipid concentration of 77
mM (step 1). The ethanol solution was injected at a flow rate of 12 ml/min into PBS (pH 7.0 -
7.5) with a flow of 80 ml/min and resulting in a total lipid concentration of 10 mM (step 2).
Dilution with ethanol led to a controlled precipitation of the lipids at the injection site, which
were subsequently rearranged to form liposomes (step 3) [14, 15]. According to the common
protocol for the preparation of plain liposomes, the removal of solvent was carried out directly
after preparation with a cut-off of 50.000 MWCO over 5 h and three buffer changes (step 4).
The coupling reaction was performed with a molar ratio of 2:1 peptide to DSPE-PEG-2000-
Mal for 1 h at room temperature under nitrogen atmosphere at pH of 7.0 (step 5). The model
peptide RVG was reduced prior to the coupling reaction with TCEP (10-fold molar excess).
Figure 1: Graphic illustration of the pre-insertion method. Liposomes were prepared by solvent injection method. DSPE-PEG-
2000-Mal, DMPC and CHO were dissolved in ethanol with a total lipid concentration of 77 mM (step 1). The ethanol solution
was injected at a flow rate of 12 ml/min into a stream of PBS (pH 7.0-7.5) with a flow of 80 ml/min (step 2), resulting in a total
lipid concentration of 10 mM. The dilution of the ethanol led to a controlled precipitation of the lipids at the injection site, which
were subsequently rearranged to form liposomes (step 3). Removal of solvent was carried out directly after preparation with a
cut-off of 50.000 MWCO over 5 h and three buffer changes (step 4). The coupling of ligand was performed after a purification
step (step 5).
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Table 1: Theoretical composition of functionalized liposome formulation, prepared by pre-insertion.
Compound Molar ratio
(mol/mol %)
Initial total lipid concentration
[mM]
Final total lipid
concentration
[mM]
Final peptide
concentration
[mM]
DMPC 0.6 46.2 6
CHO 0.35 26.95 3.5
DSPE-PEG-
2000-Mal 0.05 3.85 0.5
Peptide 0.05 0.5
2.2.2 Preparation of functionalized liposomes by post-insertion method
Figure 2: Graphic illustration of the post-insertion method. DSPE-PEG-2000-Mal and DSPE-PEG-2000 were dissolved in
methylene chloride in a molar ratio of 1:4 with total lipid concentration of 2 mM (step 1). A lipid-film was generated under
nitrogen stream by the removal of solvent (step 2). The micelles were formed by the hydration of the lipid-film with PBS to
2 mM at 40°C for 5 minutes in a water bath. Peptide was dissolved in PBS and reduced with TCEP prior to coupling reaction
(10-fold molar excess). Peptide solution was added to the micellar solution and incubated for 1h at room temperature at pH
7.00 with a molar ratio of 2:1 peptide to DSPE-PEG-2000-Mal (step 3). The micelles were inserted into preformed liposomes
composed of DOPC and CHO for one hour at 65°C in a water bath (step 4, 5).
Liposomes composed of DOPC and CHO were prepared according to the protocol described in
2.2.1 by solvent injection method and concentrated to a final total lipid concentration of 20 mM
by centrifugal filtration (Figure 2, Table 2). DSPE-PEG-2000-Mal and DSPE-PEG-2000 were
dissolved in methylene chloride in a molar ratio of 1:4 with total lipid concentration of 2 mM
(step 1). A lipid-film was generated under nitrogen stream by the removal of solvent (step 2).
The micelles were formed by hydration of the lipid-film with PBS to a concentration of 2 mM
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at 40°C for 5 minutes in a water bath. The model peptide EPRNEEK was dissolved in PBS and
reduced with TCEP prior to coupling (10-fold molar excess). Peptide solution was added to the
micellar solution and incubated for 1 h at room temperature at pH 7.00 with a molar ratio of 2:1
peptide to DSPE-PEG-2000-Mal (step 3). The micelles were finally inserted into preformed
liposomes composed of DOPC and CHO for 1 h at 65°C in a water bath (step 4, 5) [16].
Table 2: Theoretical composition of targeted liposome formulation, prepared by post-insertion.
Compound Molar ratio
(mol/mol %)
Initial total lipid
concentration
[mM]
Final total lipid
concentration
[mM]
Final peptide
concentration
[mM]
DOPC 0.6 23.1 6
CHO 0.4 15.4 4
DSPE-PEG-2000-
Mal
0.01 0.4 0.1
DSPE-PEG-2000 0.04 1.6 0.4
Peptide 0.01 0.1
2.2.3 Size and zeta potential determination
Size distribution and zeta potential (ZP) were determined by dynamic light scattering (DLS)
and Laser Doppler electrophoresis (LDE) using a Zetasizer Nano ZS Malvern Instruments
(Worcestershire, UK), equipped with a helium neon laser (λ= 633 nm). To determine size
distribution, samples were measured undiluted three times at 25 ± 0.1°C with fixed position
(4.65 nm) at a detection angle of 173° (back scatter). Data was analyzed via cumulants fit. For
the determination of ZP, samples were diluted 1:10 with Milli-Q-water and measured three
times at 25°C. ZP was calculated by Smoluchowski’s equation from the electrophoretic
mobility of liposomes.
2.2.4 Quantification of maleimide functionalized phospholipids: DSPE-PEG-2000-Mal
To determine the impact of the purification process with regard to the amount of active
maleimide groups the formulation was analyzed by HPLC and indirect Ellman´s assay during
preparation. The total amount of DSPE-PEG-2000-Mal, the sum of active and inactive DSPE-
PEG-2000-Mal molecules was obtained by HPLC analysis (see 2.2.4.1), whereas active amount
was determined by indirect Ellman´s assay (see 2.2.4.2).
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2.2.4.1 Total amount of maleimide functionalized phospholipid (DSPE-PEG-2000-Mal)
Samples of each preparation step were analyzed by RP-ELSD-HPLC using a recently published
method [17]. In brief, the micellar and liposomal samples were dissolved in a mixture of
isopropanol and water then analyzed on an Agilent 1260 HPLC system equipped with an ELSD.
Eluent A was composed of methanol and water in a volume ratio of 40:60 with 10 mM
ammonium acetate and pH-value of 6.4, which was adjusted with 1 mM acetic acid. Eluent B
was composed of methanol and isopropanol in a ratio of 10:90 with 10 mM ammonium acetate.
Separation was performed on a Kinetex Core shell column (C18, 2.6 u, 100Å, 100 x 3 mm,
Phenomenex, Aschaffenburg).
2.2.4.2 Active amount of maleimide functionalized phospholipid (DSPE-PEG-2000-Mal)
The active maleimide groups were analyzed by an indirect Ellman´s assay [18]. The reagent
solution was prepared by dissolving Ellman´s reagent in reaction buffer, 0.1 M sodium
phosphate containing 1 mM EDTA with pH 8.00, to 4 mg/ml. The maleimide-containing
samples were incubated with a cysteine solution of known concentration (5-fold molar excess)
at room temperature and pH 7.00. Free thiol-groups reacted with maleimides to form a stable
thioether-linkages. After 30 minutes the amount of non-reacted thiol groups were analyzed by
Ellman´s assay. 250 µl of the sample were added to 50 µl Ellman´s reagent (4 mg/ml) diluted
in 2.5 ml reaction buffer and incubated for 15 minutes at room temperature at pH 8.00. Ellman´s
reagent forms a mixed disulfide and a colored product with free thiol-groups of unreacted
cysteine (Figure 3). The reaction was followed spectrophotometrically at 412 nm. The amount
of active maleimides was calculated from the amount of unreacted cysteine.
Figure 3: Maleimide activity was determined by an indirect Ellman´s assay. The sample was incubated with a known amount
of cysteine. Free thiol-groups reacted with maleimides to form a stable thio-ether linkage. The amount of active maleimide was
calculated from the amount of unreacted cysteines, which were determined by the incubation with Ellman´s reagent, forming
a mixed disulfide and the colored product. The reaction can be followed spectrophotometrically at 412 nm.
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2.2.5 Activity of DSPE-PEG-2000-Mal at different pH values
As proof of concept, DSPE-PEG-2000-Mal was dissolved in PBS (0.5 mM). The pH values
were set to pH 7.0 and 9.5. Maleimide activity was analyzed over a time period of 24 h at room
temperature. Sampling was carried out after 5 and 24 h. The time-point directly after the setting
of the pH-values was defined as t= 0 h. For analysis, samples of the two solutions were treated
according to the above mentioned instructions.
2.2.6 Statistical analysis
All values are expressed as means ± standard deviation of three individual performed
experiments. Statistical data analyses were performed using Student’s t-test with p < 0.05 as
level of significance. All tests were performed using the statistical software SigmaPlot (Systat
Software, San Jose, CA).
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3. Results and discussion
The unmasking of inherent risks during preparation of maleimide functionalized liposomes with
respect to maleimide activity was the main objective of the presented work. Declared goals
were the development of a quick and easy method for the determination of active maleimide
groups, as well as the application of this method during the preparation of liposomes. RP-HPLC
was used for the determination of the total lipid content. In addition to that the formation process
and the integrity of liposomes were followed by changes in size and surface potential.
3.1. Evaluation of maleimide activity
The identification of an assay for the quick and reliable assessment of maleimide activity was
of high interest. Several methods were investigated for their suitability. The coupling reaction
could be directly monitored spectrophotometrically by assessing the decrease in absorbance at
300 nm, which is due to the disappearance of the double bond upon the nucleophile addition of
thiols [4]. However, this approach was not further followed since high quantities of thiols are
needed and the monitoring might be interfered by the double bonds of CHO and DOPC that are
also part of the liposomal composition. Using the reactivity of maleimide towards thiol-
containing compounds at neutral pH-values is another strategy to quantify maleimide activity.
Instead of the thiol-containing peptide of choice, thiol-containing fluorophores, like SAMSA
(5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino)fluorescein), can be used as reaction
partner. A drawback however, are the compulsory washing steps to guarantee that only coupled
fluorophores are detected. M. Dreher and H. Hirsch described the indirect Ellman´s reaction
[19], where the maleimide-containing sample was incubated with a thiol-containing compound.
Since the reaction stoichiometry is 1:1, the amount of active maleimides can be calculated from
the amount of non-reacted thiols, which can be detected spectrophotometrically upon reaction
with Ellman´s reagent. In contrast to the other methods, this approach is ideal for fast in-process
controls during preparation. In addition to that the indirect Ellman´s assay was successfully
used for the assessment of coupling efficiencies on polystyrene nanoparticles [20]. Therefore,
there was a tremendous motivation to apply it to the liposomal preparation process. As proof of
concept 0.5 mM DSPE-PEG-2000-Mal solutions were incubated at pH 7.0 and pH 9.5 over 24
h (Figure 4). This time period was chosen in accordance to published protocols for maleimide-
thiol-reactions [2]. Hydrolysis to the unreactive maleic acid is pH-dependent and occurs
preferably at higher pH values [4]. The DSPE-PEG-2000-Mal solution at pH 7.0 showed an
activity of 100 ± 0.6% after 24 h. As expected all maleimide groups remained stable under these
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conditions. In contrast to that the DSPE-PEG-2000-Mal solution with pH 9.5 showed a decrease
of the activity down to 18 ± 0.8% (p≤ 0.001) and 26 ± 4.5% (p≤ 0.001) after 5 and 24 h
respectively. This reflects the fact that under alkaline conditions, maleimides undergo
hydrolysis to the unreactive, ring-open form [4].
Figure 4: Maleimide activity of a DSPE-PEG-2000-Mal solution in PBS at
different pH-values (7 and 9.5) analyzed by the indirect Ellman´s assay.
The solution at pH 7.0 showed only minor decrease of activity whereas the
solution at pH 9.5 showed a massive loss of activity due to hydrolysis of
the maleimide group. (Mean ± SD, n=3). Statistical difference indicated by:
*p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
3.2 Application to different preparation methods of functionalized liposomes
3.2.1 Functionalized liposomes prepared by pre-insertion method
The preparation of functionalized liposomes by pre-insertion is depicted in Figure 1. The
solvent-injection is an approved method for the preparation of liposomes [14]. The liposomes
are directly formed by the injection of a lipid solution into an excess of buffer. The results are
summarized in Table 3. The unmasking of the critical steps with regard to maleimide activity
were achieved by analysis of size, surface charge, total amount of DSPE-PEG-2000-Mal and
maleimide activity before (step 3) and after purification (step 4). The liposomes composed of
DMPC, CHO and DSPE-PEG-2000-Mal had a size of 192 ± 5 nm with PDI of 0.20 before
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purification (step 3) and 139 ± 5 nm with PDI of <0.25 after purification (step 4). The
purification of liposomes was characterized by a decrease in size due to the removal of ethanol.
Ethanol interacts with phospholipid membranes [21] and its removal results in a reorganization
of the phospholipid membrane and causes the change in size. The surface charge was -12.8 ±
0.3 mV before purification (step 3) and -14.7 ± 1.3 mV after purification (step 4). The
monitoring of surface charge plays a significant role for maleimide functionalized DDS. The
hydrolysis causes a change of surface functionalization due to the formation of free carboxyl
groups. This was shown by Pereira et al., who analyzed surface functionalized quantum dots
by capillary electrophoresis. The migration time of quantum dots carrying hydrolyzed
maleimide groups on the outer surface was similar to the migration time of quantum dots
carrying free carboxyl groups [22]. Therefore, the increase of negative charge during the
purification can provide a first hint of hydrolyzed maleimide groups on the outer surface.
Nevertheless, further analysis was needed, as surface charge of pre-inserted liposomes can also
be affected by changes in buffer system. The formulation was further analyzed by HPLC and
indirect Ellman´s assay, to determine the impact of the purification process with regard of the
amount of active maleimide groups during preparation (Figure 5). The total amount of the
DSPE-PEG-2000-Mal decreased during the purification process from 0.49 ± 0.05 mM down to
0.44 ± 0.04 mM. The loss of lipid during purification could be explained by adsorption effects
of the dialysis membrane, removal of incompletely incorporated lipids which were not
completely incorporated or due to dilution effects [17]. A specific focus was on the active
amount of maleimides determined by indirect Ellman´s assay, which was 63% of the total
amount (p≤0.01). In contrast to HPLC analysis, where the liposomal bilayer is destroyed prior
to analysis, the investigation of active maleimide groups by indirect Ellman´s assay is directly
examined on the surface of the intact liposome. Therefore, this result could provide insights
into the orientation of functionalized PEG-chains at the liposomal bilayer. The PEGylated
phospholipids are part of the organic lipid phase, which is injected into the aqueous phase.
During this process the PEG-chain ends carrying the maleimide groups can be oriented towards
the liposome core as well as towards the outside [13]. The indirect Ellman´s assay detected 63%
of the initial maleimide groups. These results reveal a maleimide distribution of approximately
two-thirds on the surface, available for conjugation, and one-third towards the inner liposome´s
core. Although the analysis was performed with intact liposomes, the diffusion of Ellman´s
reagent into the inner core could cause false-positive results. However, since Ellman´s reagent
is hydrophilic and is negatively charged at pH 8.00 its diffusion rate across the liposomal wall
was assumed to be negligible.
Results and discussion
101
The further decrease of activity during purification to 32% (p≤0.01) impressively showed the
impact of manufacturing with respect to maleimide activity. According to the common protocol,
the purification was done by dialysis over a time period of 5 h. The maleimide groups protruded
from the liposomal surface and were in close contact to aqueous media, which could cause the
loss of activity. In case of the pre-insertion method the purification was identified as the most
critical step with respect to maleimide activity. As a consequence the coupling reaction could
be performed prior to the purification step. Performing the coupling reaction prior to
purification might be beneficial with regard to maleimide activity, but may enhance the creation
of undesired coupling products. This fact becomes especially critical for liposomal formulations
that carry a cargo. Hydrophilic cargos are encapsulated during the liposome formation process
(step 3) [23]. Free and non-encapsulated cargo could compete with a ligand intended for being
immobilized on the surface for targeting purposes for maleimide-thiol coupling. Therefore prior
purification is of high importance. In case of the preparation of maleimide-functionalized
liposomes by pre-insertion method, dialysis is not the purification method of choice due to its
impact on maleimide activity and should be replaced by other purification techniques like
tangential flow filtration (TFF) or gel filtration [24, 25]. Nevertheless, the impact on maleimide
activity of these techniques still needs to be investigated and was not part of the presented work.
Figure 5: Comparison of theoretical amount, total amount and active
amount of DSPE-PEG-2000-Mal before and after purification during
liposomal preparation by pre-insertion method. Liposome was composed
of DMPC, CHO and DSPE-PEG-2000 Mal. (Mean ± SD, n=3) Statistical
difference indicated by: *p≤ 0.05, ** p ≤ 0.01, *** p≤ 0.001.
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Table 3: Summary of physicochemical characterization of maleimide-functionalized liposomal formulations prepared by pre-
insertion method. (Mean ± SD, n=3). Determined by DLS1, LDE2, RP-ELSD-HPLC3, Indirect Ellman´s assay4.
Preparation
method
Preparation
step
Liposome
composition
Size1
[nm] PDI
1 Zeta potential2 [mV]
Total amount of
DSPE-PEG-
2000-Mal3 [mM]
Maleimide
activity4
[%]
Pre-
insertion
Before
purification DMPC:CHO:DSPE-
PEG-2000-Mal
192 ± 5
0.200
±
0.003
-12.8 ± 0.3 0.49 ± 0.05 63
After
purification 139 ± 5
0.220
±
0.006
-14.7 ± 1.3 0.44 ± 0.04 32
3.2.2 Functionalized liposomes by the post-insertion method
As an alternative to the pre-insertion method, functionalized liposomes were prepared by the
post-insertion method. In contrast to the pre-insertion method, post-insertion comprises two
consecutive reactions. First, micelles are formed with DSPE-PEG-2000-Mal in the presence of
aqueous phase and subsequently model peptide EPRNEEK was coupled to the PEG ends. These
ligand-modified micelles were then inserted in preformed liposomes [13, 26, 27]. The
preparation steps are depicted in Figure 2. Micelles, composed of DSPE-PEG-2000 and DSPE-
PEG-2000-Mal, were prepared prior to the coupling reaction (step 1, 2, 3). The peptide-
functionalized micelles were then inserted into preformed liposomes (step 4, 5). Liposomes
prepared post-insertion were again analyzed by the assessment of size, charge, total and active
DSPE-PEG-2000-Mal amount to identify the critical steps of preparation (Table 4 and Figure
6-8). The liposomes, composed of DOPC and CHO, had a size of 62 ± 4 nm with PDI <0.19.
These size ranges could be achieved with an initial lower total lipid concentration of 38.5 mM
in the ethanol solution. The micelles had a size of 16.0 ± 0.2 nm with a PDI of <0.13 (step 3),
which increased after the coupling reaction with the model peptide EPRNEEK in size to 20 ±
3 nm with a PDI <0.25 (step 4). The narrow size distribution was achieved by addition of DSPE-
PEG-2000 to the micellar composition. Finally, when the peptide-functionalized micelles were
incubated with the preformed liposomes, particles with a size of 65 ± 3 nm and PDI of <0.2
(step 4, 5) were obtained. Figure 7 shows that the zeta potential measurements proved the
insertion of micelles into the liposomes. While the preformed liposomes had a neutral charge
(-0.7 ± 3.5 mV), the incorporation of peptide-functionalized micelles (-17.3 ± 4.5 mV) into the
liposomes resulted in the negatively charged liposomes after post-insertion (-18.53 ± 0.8 mV)
[28]. DSPE-PEG-2000 and DSPE-PEG-2000-Mal lose their zwitterionic property due to the
linking of PEG-chain to free primary amino group via carbamoyl linkages [28], resulting in a
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negative charge. Surface charge of peptide-functionalized micelles and post-inserted liposomes
was within the same range. An increase of negative surface charge due to the formation of free
carboxyl groups of hydrolysis product was not observed.
Directly after the micelle formation (step 3), samples were analyzed with respect to total amount
of DSPE-PEG-2000 and DSPE-PEG-2000-Mal and maleimide activity (Figure 8). Contrary to
the liposomes prepared by pre-insertion method, the formulations also contained DSPE-PEG-
2000. The HPLC analysis provided information about the total amount of both PEG-lipids but
was not able to distinguish between them. The micelles had a concentration of 1.71 ± 0.02 mM.
The amount of active maleimide groups was determined by indirect Ellman´s assay. 76% of the
maleimide groups were available for coupling reaction directly after the micelle preparation.
Although the post-insertion process avoided long contact to the aqueous phase, the results
revealed that the solvent removal as well as the hydration of lipid-film for the generation of
micelles already had measurable effects on maleimide activity. After the coupling of the model
peptide, the micelles were inserted into preformed liposomes with an amount of 0.42 ± 0.03
mM. The samples were finally purified by centrifugal filtration. The purified sample showed
no change in liposome composition after the purification, indicating the complete insertion of
PEGylated lipids (data not shown).
Figure 6: Size of liposomes prepared by the post-insertion method by DLS. The preformed
liposomes were composed of CHO and DOPC with a molar ratio of 0.6:0.4 (AP). The micelles
were composed of DSPE-PEG-2000 and DSPE-PEG-2000-Mal with a molar ratio of 0.04:0.01
(Mic). Mic-Ac showed the DLS results, after the coupling of model peptide. Finally, peptide-
functionalized peptides were inserted into preformed liposomes (PT). (Mean ± SD, n=3) AP: after
purification; MIC: micelle; MIC-AC: micelle after coupling; PT: post insertion.
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Figure 7: Zeta potential of prepared liposomes by the post-insertion method. The preformed
liposomes were composed of CHO and DOPC with a molar ratio of 0.6:0.4 (AP). The micelles were
composed of DSPE-PEG-2000 and DSPE-PEG-2000 Mal with a molar ratio of 0.04:0.01 (Mic). Mic-
Ac showed the surface charge after the coupling of model peptide. Finally peptide-functionalized
peptides were inserted into preformed liposomes (PT).(Mean ± SD,n=3)AP: after purification; MIC:
micelle; MIC-AC: micelle after coupling; PT: post insertion.
Figure 8: Amount of DSPE-PEG-2000 and DSPE-PEG-2000-Mal, determined by HPLC, and the
active amount of DSPE-PEG-2000-Mal, determined by indirect Ellman´s assay, in the micelle
sample directly after hydration compared to the initial concentration of both PEG-lipids.(Mean ±
SD, n=3).
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Table 4: Summary of physicochemical characterization of maleimide-functionalized liposomal formulations prepared by post-
insertion method. (Mean ± SD, n=3). Determined by DLS1, LDE2, RP-ELSD-HPLC3, Indirect Ellman´s assay4.
Preparation
method
Preparation
step Composition
Size1
[nm] PDI
1 Zeta potential2
[mV]
Total amount of
DSPE-PEG-
2000+DSPE-
PEG-2000-Mal3
[mM]
Maleimide
activity4
[%]
Post-
insertion
After
purification DOPC:CHO 62 ± 4
0.187 ±
0.004 -0.7 ± 3.5 - -
Micelle
DSPE-PEG-
2000:DSPE-PEG-
2000-Mal
16.0 ± 0.2 0.13 ± 0.02 -8.8 ± 3.9 1.71 ± 0.02 76
Micelle-
After
coupling
DSPE-PEG-
2000:DSPE-PEG-
2000-
Mal+EPRNEEK
20 ± 3 0.211 ±0.014 -17.3 ± 4.5 1.71 ± 0.02 -
After post-
insertion
DOPC:CHO:
DSPE-PEG-
2000:DSPE-PEG-
2000-
Mal+EPRNEEK
65 ± 3 0.161 ±0.021 -18.53 ± 0.8 0.42 ± 0.03 -
4. Conclusion
The hydrolysis of maleimide groups is a crucial factor during the preparation of maleimide-
functionalized liposomes. The loss of reactivity against thiol-containing peptides and increase
of negative charge due to the formation of free carboxyl groups, changes dramatically the
uptake of DDS by cells. Our proposed indirect Ellman´s assay unmasked critical preparation
steps of two common methods for the preparation of DSPE-PEG-2000-Mal functionalized
liposomes. By this, the method can not only be used for the stability assessment of preparation
methods with regard to maleimide activity, but furthermore reveal the number of active
maleimide groups located on the outer surface of liposome or micelle prior to the coupling
reaction.
Chapter 5 - Determination of the activity of maleimide-functionalized phospholipids during
preparation of liposomes
106
Reference List
1. Kim, J.-Y., et al., Brain-targeted delivery of protein using chitosan-and RVG peptide-
conjugated, pluronic-based nano-carrier. Biomaterials, 2013. 34(4): p. 1170-1178.
2. Tao, Y., J. Han, and H. Dou, Brain-targeting gene delivery using a rabies virus
glycoprotein peptide modulated hollow liposome: bio-behavioral study. Journal of
Materials Chemistry, 2012. 22(23): p. 11808-11815.
3. Christie, R.J., et al., Stabilization of cysteine-linked antibody drug conjugates with N-
aryl maleimides. Journal of Controlled Release, 2015. 220, Part B: p. 660-670.
4. Hermanson, G.T., Chapter 3 - The Reactions of Bioconjugation, in Bioconjugate
Techniques (Third edition). 2013, Academic Press: Boston. p. 229-258.
5. Nair, D.P., et al., The thiol-Michael addition click reaction: a powerful and widely used
tool in materials chemistry. Chemistry of Materials, 2013. 26(1): p. 724-744.
6. Brinkley, M., A brief survey of methods for preparing protein conjugates with dyes,
haptens, and cross-linking reagents. Bioconjugate chemistry, 1991. 3(1): p. 2-13.
7. Khan, M.N., Kinetics and Mechanism of the Alkaline Hydrolysis of Maleimide. Journal
of Pharmaceutical Sciences, 1984. 73(12): p. 1767-1771.
8. Mattson, G., et al., A practical approach to crosslinking. Molecular biology reports,
1993. 17(3): p. 167-183.
9. Fröhlich, E., The role of surface charge in cellular uptake and cytotoxicity of medical
nanoparticles. Int J Nanomedicine, 2012. 7(1): p. 5577-91.
10. Kelf, T.A., et al., Non-specific cellular uptake of surface-functionalized quantum dots.
Nanotechnology, 2010. 21(28): p. 285105.
11. Patterson, J.T., et al., Improving the serum stability of site-specific antibody conjugates
with sulfone linkers. Bioconjugate chemistry, 2014. 25(8): p. 1402-1407.
12. Tumey, L.N., et al., Mild method for succinimide hydrolysis on ADCs: impact on ADC
potency, stability, exposure, and efficacy. Bioconjugate chemistry, 2014. 25(10): p.
1871-1880.
13. Nag, O.K. and V. Awasthi, Surface engineering of liposomes for stealth behavior.
Pharmaceutics, 2013. 5(4): p. 542-569.
14. Batzri, S. and E.D. Korn, Single bilayer liposomes prepared without sonication.
Biochimica et Biophysica Acta (BBA) - Biomembranes, 1973. 298(4): p. 1015-1019.
15. J.S. Dua, P.A.C.R., Dr. A.K. Bhandari, LIPOSOME: METHODS OF PREPARATION
AND APPLICATIONS. International Journal of Pharmaceutical Studies and Research,
2012. 3(2): p. 14-20.
16. Marqués-Gallego, P. and A.I.P.M. de Kroon, Ligation strategies for targeting liposomal
nanocarriers. BioMed research international, 2014. 2014.
17. Oswald, M., et al., HPLC analysis as a tool for assessing targeted liposome
composition. International Journal of Pharmaceutics, 2016. 497(1–2): p. 293-300.
18. Ellman, G.L., A colorimetric method for determining low concentrations of mercaptans.
Archives of biochemistry and Biophysics, 1958. 74(2): p. 443-450.
19. Dreher, M. and H. Hirsch, Method for the determination of maleimide groups. 1992,
Google Patents.
20. Moser, M., et al., Quantification of PEG-maleimide ligands and coupling efficiencies
on nanoparticles with Ellman’s reagent. Analytical chemistry, 2015. 87(18): p. 9376-
9383.
21. Barry, J.A. and K. Gawrisch, Direct NMR Evidence for Ethanol Binding to the Lipid-
Water Interface of Phospholipid Bilayers. Biochemistry, 1994. 33(26): p. 8082-8088.
22. Pereira, M. and E.P.C. Lai, Capillary electrophoresis for the characterization of
quantum dots after non-selective or selective bioconjugation with antibodies for
immunoassay. Journal of Nanobiotechnology, 2008. 6(1): p. 10.
Reference list
107
23. Akbarzadeh, A., et al., Liposome: classification, preparation, and applications.
Nanoscale Research Letters, 2013. 8(1): p. 102-102.
24. Guichardon, P., et al., Comparative study of semi-solid liposome purification by
different separation methods. Separation and purification technology, 2005. 41(2): p.
123-131.
25. Torchilin, V. and V. Weissig, Liposomes: a practical approach. 2003: Oxford
University Press.
26. Iden, D.L. and T.M. Allen, In vitro and in vivo comparison of immunoliposomes made
by conventional coupling techniques with those made by a new post-insertion approach.
Biochimica et Biophysica Acta (BBA)-Biomembranes, 2001. 1513(2): p. 207-216.
27. Uster, P.S., et al., Insertion of poly (ethylene glycol) derivatized phospholipid into pre-
formed liposomes results in prolonged in vivo circulation time. FEBS letters, 1996.
386(2): p. 243-246.
28. Garbuzenko, O., et al., Electrostatics of PEGylated Micelles and Liposomes Containing
Charged and Neutral Lipopolymers. Langmuir, 2005. 21(6): p. 2560-2568.
Chapter 5 - Determination of the activity of maleimide-functionalized phospholipids during
preparation of liposomes
108
Supplementary material
Post insertion of micelles – Dynamic light scattering
Size distribution was determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS
Malvern Instruments (Worcestershire, UK), equipped with a helium neon laser (λ= 633 nm).
Samples were measured undiluted three times at 25 ± 0.1°C with fixed position (4.65 nm) at a
detection angle of 173° (back scatter). Data was analyzed via cumulants fit. Figure 1 depicts
the overlay of the size distribution graph of a micelle sample (red) and a final liposome
preparation after post insertion (green). A single symmetrical peak indicating the existence of
a homogeneous population that is larger than the micelles characterizes the size distribution
graph of the liposome formulation.
Figure 1: Overlay of a micelle sample (red) and liposome after post insertion (green).
SEC analysis
Post-insertion of micelles into liposomes was also followed by size exclusion chromatography
(SEC) analysis. Micelles, liposomes and the final liposome formulation after post-insertion
were injected into a HPLC system (Agilent 1260) quipped with diode array detector (DAD).
Phosphate buffered saline (PBS) was used as eluent. Size exclusion chromatography was
performed on a TSKgel 4000 PWxl column (7.8 mm x30 cm; 10 µm particle size; exclusion
limit dextran: 1000 kDa), with a flow rate of 0.6 ml/min over 30 minutes.
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Chromatograms obtained for each of the three preparations (micelles, liposomes and liposomes
after the post-insertion) nicely confirm the integration of micelle material into the liposomes
(Figure 2). Preformed liposomes eluted first due to their large size followed by the micelles and
the free peptide. The chromatogram of the final liposome formulation confirmed the success of
micelle ’insertion’ by the disappearance of the micelle peak.
Figure 2: Results of SEC analysis. The preformed liposomes (blue line) were made of DOPC and CHO with a molar
ratio of 0.6:0.4. The micelles (petrol blue) contained DSPE-PEG-2000 and DSPE-PEG-2000-Mal with a molar ratio of
0.04:0.01 (Mic). Finally, peptide-functionalized phospholipids were inserted into preformed liposomes (green).
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Abstract
The purpose of the presented work was the analysis of the fundamental characteristics of
liposomal formulations for brain endothelial cell uptake. Aside from the functionalization of
liposomes with special recognition motifs for blood-brain barrier (BBB) targeting, other factors
may support particle internalization. The presented work depicts the impact of size, charge,
degree of PEGylation and the addition of the brain-specific polyunsaturated fatty acid
docosahexaenoic acid (DHA) of liposomal formulations on the binding to the brain endothelial
cell line bEND.3. Flow cytometry analysis revealed enhanced binding for positively charged,
non-PEGylated liposomes. In contrast, size and PEG density showed only minor effects on cell
binding. The findings have important implications for providing guidance on the formulation
development of BBB-targeted liposomes. They underline the importance of adjusting
physicochemical properties for targeted drug delivery.
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1. Introduction
The blood-brain barrier (BBB) is a highly regulated and controlled barrier of our body [1–3].
Therefore, it is not surprising that the development of BBB-targeted formulations require tailor-
made properties with respect to their physicochemical properties and active targeting strategies.
While most of the published data focusses on active targeting strategies making use of ligands
such as transferrin [4–6], apolipoprotein E [7, 8] or rabies virus glycoprotein [9–11],
physicochemical properties of drug delivery systems (DDS) are often neglected. This is
astonishing as defined settings for size, charge and liposome composition could directly impact
the uptake of actively targeted liposomes [12]. As a consequence, a careful analysis of the
physicochemical properties of DDS is highly required to determine particle-inherent passive
targeting effects.
A major characteristic of the BBB is its selective uptake of molecules [13]. A lack of
fenestrations and the existence of tight junction proteins between endothelial cells ensure that
molecules with a molecular weight above 500 Da are not able to use paracellular pathways [13].
Consequently, the uptake of BBB-specific liposomes is controlled by endocytotic mechanisms
[14]. The underlying mechanisms are strongly related to the physiochemical properties of the
compound. For example, in the case of clathrin-mediated endocytosis, endocytosed vesicles
have a diameter of 100–150 nm, which is a typical size of DDS prior to it being endocytosed
[15, 16]. Furthermore, the charge or the composition of the liposome can also impact the
unspecific uptake behaviour. Electrostatic and hydrophobic interactions between the liposome
and the cell membrane have been reported to result in an adsorptive-mediated uptake of
liposomes [12]. What is more, the PEGylation of liposomes, which is highly required for a
reduced recognition by macrophages, could also cause a reduced unspecific uptake on target
cells [17]. The impact of physicochemical properties should accordingly always be addressed
in the context of delivering liposomes across the BBB.
The brain endothelial cell line bEnd.3 is well suited as a cellular uptake model, since it has
important blood-brain barrier (BBB) characteristics [18]. Figure 1 depicts a microscopic picture
of a bEND.3 cell line monolayer.
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Figure 1 depicts the microscopic picture of bEND.3 cells after day three of seeding.
The cells were seeded in a 24-well plate with a density of 12x105 per well. The image
shows the characteristic spindle shaped morphology.
Omidi et al. characterized the bEND.3 cell line regarding its use as an in vitro BBB model for
drug uptake and transport studies [18]. They showed that the cells express several vesicle-
associated proteins and important transporters and receptors of the BBB such as glucose and
amino acid carriers and P-glycoprotein. It is, therefore, not surprising that the bEnd.3 cell line
is a popular in vitro model for studying interactions of DDS with the BBB [7, 10, 19, 20].
The aim of the presented work was to identify beneficial physicochemical properties for BBB-
specific liposomes by applying different liposomal formulations to a well-established in vitro
model for BBB-targeting effects [18]. By doing so, the present work gives a deeper insight into
the tailor-made development of BBB-specific liposomes.
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2. Materials and methods
2.1. Materials
Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) (InvitrogenTM, Carlsbad
(USA), Cat.No: 41965) with 10% fetal bovine serum (FBS) (PAN-Biotech, Aidenbach
(Germany), Cat.Nr.: 1502-P121511) and 1 mM Sodium-Pyruvate (InvitrogenTM, Carlsbad
(USA), Cat.No.:11360). Penetratin 5-FAM was used as positive control and was obtained from
Innovagen (Innovagen AB, Lund [Sweden]). Phosphate buffered saline (PBS) (1x) was
obtained from Gibco (Life technologiesTM, Carlsbad [USA]). Accutase was used for the
detachment of cells and bought from Innovative cell technologies (San Diego, USA). 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (ammonium salt) (Avanti
Polar Lipids, Inc., Alabaster [USA]) and Dextran, Fluorescein, 10,000 MW, Anionic (Thermo
Fisher Scientific, Inc. Waltham [USA]) was used for the labelling of liposomal formulations.
2.2. Methods
2.2.1 Liposome preparation and characterization
The preparation and characterisation of liposomes are described in chapter 2. Table 1 gives an
overview of the liposome formulations used.
2.2.2 Labeling of liposomes
Fluorescein dextran with a molecular weight of 10.000 Da dissolved in PBS (0.05 mM) was
encapsulated into the liposomes for analytical purposes. Purification of liposomal samples was
performed via dialysis against PBS with a 50.000 MWCO slide-a-lyzer. Final total lipid
concentration was adjusted to 10 mM. Particle size and charge were analyzed by dynamic light
scattering (DLS) and laser diffraction electrophoresis (LDE) using a Zetasizer Nano ZS from
Malvern Instruments (Worcestershire, UK), equipped with a helium neon laser (λ= 633 nm).
For size-distribution analysis samples were measured undiluted at 25 ± 0.1°C with fixed
position (4.65 nm) at a detection angle of 173° (back scatter). The data was analyzed via
cumulants fit. For the determination of zeta potential, samples were diluted tenfold with Milli-
Q-water and measured at 25°C. ZP was calculated using Smoluchowski’s equation, which
describes the electrophoretic mobility of liposomes. All measurements were performed in
triplicate.
Chapter 6 - In vitro analysis of blood-brain barrier (BBB) specific liposomes: understanding
the impact of tailoring formulation properties
116
2.2.3 Endotoxin level
Endotoxin level of all formulations were assessed prior to in vitro testing by using the
Endosafe®-PTSTM (Charles River Laboratories International, Inc, Wilmingtion [USA]).
Endotoxin level was below 0.1 EU/ml for all formulations.
2.2.4 Cell culture media stability of liposomes
The physical stability of liposomes was analyzed after the incubation with cell culture media.
To this end, liposome dispersions were diluted with culture media in a ratio of 1:10.
Aggregation was analyzed by DLS, after an incubation time of 1h at room temperature.
2.2.5 Cell viability
The cell viability test was kindly performed by Mie Kristensen (Department of pharmacy,
University of Copenhagen). The cytotoxicity of prepared liposome formulations was conducted
by MTS ([3-(4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-
tetrazolium)/PMS (phenazine methosulfate) assay. Mouse brain endothelial cell line bEND.3
was chosen for the assessment of cytotoxicity. Cells were seeded in growth medium at 37°C in
a CO2 humidified atmosphere in 96-well plates 24 h before the cell viability assay. Cytotoxicity
was assessed over a concentration range of 0.125-2 mM total lipid. As positive toxic control,
0.2% SDS was used and buffer-treated cells as negative control. All formulations and controls
were prepared as solution in Hanks balanced salt solution (HBSS) with 10 mM HEPES
(hHBSS) at pH 7.4 immediately before the application to the cells. Cells were incubated with
100 µl of sample or control solution for 4 h (50 rpm, 37°C). After 4 h of incubation, the samples
and controls were discarded and the cells were washed twice with 200 µl hHBSS. Then, 100 µl
of MTS/PMS solution was added to the cells and incubated for 1.5 h (50 rpm, 37°C) under light
protection. After incubation, absorbance (492 nm) was measured on a plate reader system. The
relative cell viability was calculated as follows. The dehydrogenase activity in untreated cells
was set to 100%.
(%) = ×100viability (%)
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Where A is the absorbance obtained for each of the concentrations of the test substance, S is
the absorbance obtained for the 0.2% SDS and CM is the absorbance obtained for untreated
cells (incubated with buffer). All experiments were performed in triplicate.
2.2.6 Cellular uptake assay
Cellular uptake studies were performed using again bEnd.3 cells. The cells were seeded at a
density of 100.000 cells per well in 24 flat-bottom-well plates for 72 h at 37°C and 10% CO2
humidified atmosphere. DMEM supplemented with 10% FBS, 1 mM Sodium-Pyruvate was
used as uptake buffer. Liposomes were diluted with uptake medium to a total lipid concentration
of 0.1 mM labelled with 0.05 mM Fluorescein-Dextran. A 5 µM solution of cell-penetrating
peptide (CPP) Penetratin-5-FAM was used as positive control. For control of cell barrier
integrity a solution of free Fluorescein-Dextran (5 µM) was analyzed. Untreated cells served as
negative control. After 72 hours, cells were removed and washed twice with PBS. Thereupon,
cells were incubated with 500 µl of sample solution for 1 h at 37°C and 10% CO2. All samples
were prepared in triplicate. After the incubation time, the uptake medium was removed and the
cells were washed twice with PBS. For the flow cytometry analysis, the cells were incubated
with 100 µl accutase. After cell detachment, they were transferred in a V-bottom shaped 96-
well-plate. Cellular uptake was analyzed by flow cytometry (iQueScreener; IntelliCyt
Corporation; San Mateo [USA]). Samples were pulled out for 8 seconds (sip time) of each well.
The data consisted of sideward scatter, forward scatter and fluorescence emission at 530/30 nm
(FL-1). The data was analyzed with the ForeCyt Software (San Mateo, [USA]). Only the cell
events of the single, viable cell population were used for analysis.
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3. Results and discussion
The aim of the presented work was to determine key characteristics of brain-targeted liposomes.
As a first step, the stability of liposomes in cell culture medium and the potential cytotoxic
effects on bEND.3 cells were assessed. The CPP penetratin and fluorescein-dextran-loaded
liposomes were used to investigate binding to bEnd.3 cells. Finally, the cell model was used to
assess different potential key characteristics of liposomes like size, charge, PEGylation amount
or the addition of the brain-specific polyunsaturated fatty acid DHA in the liposome
composition.
3.1. Physicochemical characterization
Table 1 gives an overview of the liposome formulations used, as well as liposome composition
and physicochemical properties.
Table 1: Summary of used liposome formulations. The table provides information on liposome composition, total
lipid concentration (TLC) and physicochemical characteristics, like size distribution and surface charge. All
liposome formulations were prepared and analyzed in triplicate. (*=n=1,).
Liposome
formulation
Liposome composition (molar
ratio)
Cell viability DOPC CHO DSPE-PEG2000
TLC
[mM] Size [nm] PDI Zeta potential [mV]
60 35 5 10 104 <0.25 -15
Size
DOPC CHO DSPE-PEG2000 TLC[mM] Size [nm] PDI Zeta potential [mV]
60 35 5
20 489 ± 84 < 0.67 -12 ± 2
10 103 ± 13 < 0.25 -14 ± 2
5 70 ± 5 < 0.20 -15 *
Charge DMPC CHO DOTAP TLC [mM] Size [nm] PDI Zeta potential [mV]50 30 20 10 152 ± 5 < 0.37 + 20 ± 4
PEG-Amount
DOPC CHO DSPE-PEG2000 TLC [mM] Size [nm] PDI Zeta potential [mV]
62 37 1
10
112 ± 37 <0.23 n.a
60 35 5 104 ± 13 <0.25 n.a
57.5 32.5 10 81 ± 9 <0.25 -11*
DHA DOPC CHO DHA TLC [mM] Size [nm] PDI Zeta potential [mV]50 33 17 10 74 ± 2 <0.25 -25 ± 4
3.2. Cell culture media stability of liposomes
One important step prior to the contact of drug delivery systems (DDS) with cells is the stability
testing of the used formulations with the used culture media. In interaction with biological
fluids, nanoparticle adsorb proteins on their surface [21]. This adsorption of proteins is known
as the protein corona [22]. As the protein corona can massively affect the properties of DDS
[22, 23], all formulations should be tested with respect to their stability in cell culture media.
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This is illustrated in Figure 1 for a placebo liposome formulation composed of DOPC, CHO
and DSPE-PEG-2000. The formulation was incubated with DMEM supplemented with 10%.
FBS in a ratio of 1: 10, over a 1-h time period at room temperature. Size analysis was performed
prior to the incubation (0 minutes) and after 10, 30 and 60 minutes. The incubation of the
placebo liposomes with DMEM + 10% FBS results in a decrease of size from 102 ± 6 nm to
less than 90 nm after 10 minutes and in an increase of PDI (<0.30). No aggregation of liposomes
or adsorption of FBS was observed, which would have resulted in an increase in size.
Figure 2 depicts the media stability testing of liposome formulations. A placebo liposome formulation composed of DOPC,
CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5 and final lipid concentration of 10 mM was incubated with DMEM
supplemented with 10% FBS in a ratio of 1:10. Left: The graph shows an overlay of the size distribution by intensity of
DMEM+10% FBS (green), the placebo liposome formulation (red) and after the incubation of DMEM+10% FBS (blue). Right:
Samples were incubated with cell culture media over 1h at room temperature. Size analysis was assessed before (0 min) and
after 10, 30 and 60 minutes of incubation (Mean ± SD, n=3 samples).
3.3. Cell viability
Cell viability was assessed by using the MTS/PMS assay with bEND.3 cells (Figure 2). Cells
were incubated with the phosphatidylcholine (PC) liposome formulation. The PC liposome
formulation was composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), cholesterol
(CHO) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-2000] (DSPE-PEG-
2000) in a molar ratio of 60:35:5. The reagent solution MTS/PMS was added to all cells. The
metabolic activity of viable cells results in the reduction of MTS to the coloured formazan
product. The liposome formulation showed no cytotoxic effects over a concentration range of
0.125–1 mM. Cell viability decreased at a concentration of 2 mM to 84 ± 18% for the DOPC
formulation. The high standard deviation could be explained by a difference in the metabolic
activity of the cells. The metabolic activity of viable cells is used to convert MTS to the coloured
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formazan product. The differences in metabolic activity have been reported to have an impact
on the intensity of the signal [24].
Figure 3 depicts the assessment of cell viability after the incubation of bEND.3 cells with a DOPC liposome
formulation. Cell viability was assessed over a concentration range of 0.125–2 mM. Buffer-treated cells were used as
negative control. Cells treated with 0.2% SDS served as positive control. Each sample was measured in triplicate
(Mean ± SD, n=3).
3.4. Cell binding studies
Cellular binding studies employed the analysis by flow cytometry. A decisive factor in such
studies is the application of controls to ensure the functionality. Consequently, two controls
were selected. The cell-penetrating peptide (CPP) penetratin showed cellular uptake on brain
endothelial cells [25] and was, therefore, used as positive control. Penetratin is derived from
amphiphilic Drosophila Antennapedia homeodomain and is a 16 amino acid peptide. It belongs
to the arginine-rich CPPs [26]. A possible uptake could be due to electrostatic and hydrophobic
interactions between the residues of penetratin and the cell membrane (e.g. heparan sulphate
proteoglycans, phospholipids) [26]. Fluorescein dextran (10.000 Da) served two purposes in
this study: as label for the aqueous compartment of the liposomes and as control of cell barrier
integrity. Due to their hydrophilic nature and high molecular weight (10.000 Da), dextrans are
not able to pass an intact BBB via the paracellular or transcellular pathway nor the bilayers of
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liposomes. Therefore, a control group of cells treated with F-Dextran solution was used for
checking barrier integrity [27].
As a first step, the two controls, penetratin (5 µM) and F-Dextran (5 µM), were applied to the
in vitro model over 5 h (Figure 4). The aim was to prove the functionality of the designated
controls and to define an appropriate incubation time. The results are given as the mean
fluorescence intensity. Cells incubated with penetratin showed a high fluorescence signal at all
three time points. The increase of the fluorescence signal for dextran-treated cells after 5 h
indicated a loss of cell barrier integrity. This was further underlined by a decrease of the
fluorescence signal of penetratin-treated cells. This decrease could be the result of toxicological
effects and it was also accompanied with a decrease in cell counts (data not shown). Due to the
decrease of fluorescence intensity of penetratin and the increase of fluorescence intensity of
fluorescein dextran, we decided to perform further experiments with an incubation time of 1
hour.
Figure 4: Cellular binding of positive control penetratin (5 µM) in bEND.3 cell line after 1,3 and
5h. Results are given as the mean fluorescence intensity. Cell barrier integrity was checked with
fluorescein dextran (5 µM). Buffer treated cells were used as negative control (Mean ± SD, n= 3).
After it had been established, the in vitro model was applied to several liposome formulations.
Figure 5a depicts the cell binding of different sized liposomes. The liposomes were composed
of DOPC, CHO and DSPE-PEG-2000 in a molar ratio of 60:35:5 and were manufactured in
three different size ranges of 70 ± 5 nm (PDI: <0.20), 103 ± 13 nm (PDI: <0.25) and 489 ± 84
nm (PDI:<0.67). All liposome formulations were negatively charged with a zeta potential
around -15 mV. After an incubation time of 1 h, the liposomes with the smallest size showed
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some higher values compared to untreated cells with 2.1 ± 0.5% compared to 1.4 ± 0.2%,
however, it was still below the signal of free fluorescein dextran control with 2.3 ± 0.4%.
As discussed above in chapter 2, the particle diameters of less than 100 nm were considered to
be ideal for the uptake by brain endothelial cells [13, 28, 29]. The results reported by Sonavane
et al. showed that after intravenous injection of different-sized gold nanoparticles into mice, the
uptake of 15 nm gold nanoparticles was 500 times higher than the uptake of 100 nm gold
nanoparticles [30]. The lowest particle size of liposomes formulation in this study was limited
to 50 nm and could be, therefore, a likely reason for the missing uptake of the liposomes.
Another factor, which can also impact the cell uptake, is the PEG density on the liposomes.
PEGylated lipids are widely used in liposome formulations for reducing the recognition by
reticuloendothelial system [31]. However, the amount of PEG on the liposome surface might
also effect the recognition of target cells [17]. Therefore, we applied DOPC liposomes with
different PEG amount, respectively 1, 5 and 10% (Figure 5b) to the in vitro model.
Interestingly, none of the PEGylated formulations showed an uptake in the bEnd.3 cell line.
These results were in accordance with those of Shilo et al., who analyzed barbiturate conjugated
gold nanoparticles with different sizes from 20–110 nm and used PEGylated gold nanoparticles
as control. While the 70 nm barbiturate gold nanoparticle showed the highest uptake, the
PEGylated ones showed no uptake in the bEND.3 cell line [19].
In the next step, non-PEGylated liposomes with a positive charge were applied to the cell-
culture model (Figure 5c). The liposomes had a positive charge of +20 ± 4 mV and were
composed of DMPC, CHO and DOTAP with a molar ratio of 50:30:20. In contrast to the other
liposome formulations, the DOTAP liposomes showed a somewhat higher uptake of 4.9 ± 0.1%
compared to 1.4 ± 0.1% of the negatively charged liposomes or 2.3 ± 0.4% of the FITC-
Dextran-treated cells. These results showed that the uptake of liposomes in bEND.3 cells is
impacted by their surface charge. The influence of the charge was further underlined by the
positive control penetratin, whose uptake can also be explained by electrostatic interactions.
To our surprise, even the brain-specific DHA liposomes showed no uptake in bEND.3 cells
(Figure 5d).
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Figure 5: Cellular uptake of liposome formulations by brain endothelial bEnd.3 cells. Liposome uptake was investigated
as a function of size (a), PEGylation degree (b), charge (c) or the addition of the brain-specific DHA (d). Penetratin
was used as positive control (5 µM) in bEnd.3. Results are given as the percentage of the mean fluorescence intensity
of the positive control of penetratin. Cell barrier integrity was checked with fluorescein dextran (5 µM). Buffer-treated
cells served as negative control (Mean ± SD, n=3).
These results show that the unspecific uptake of liposomes in brain endothelial cells can be
clearly impacted by a positive charge. To our surprise, neither the size nor the PEGylation
degree affected the uptake of the liposomes. Hence, for BBB-targeted liposomes positive charge
seems to be a key characteristic. However, positive charge alone will not be sufficient for the
BBB penetration by liposomes. The presented results rather emphasize the need for an
additional functionalization of BBB-specific liposomes with targeting ligands.
4. Conclusion
A well suitable in vitro model for the investigation of BBB-targeted nanomaterials was
established. The influence of several physicochemical properties of liposomes on the brain
endothelial cell uptake could be assessed. The presented results give direction on relevant
factors for BBB specific liposomes with positive charge as an important characteristic.
a b
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Summary
The blood-brain barrier (BBB) is an extremely selective barrier that prevents undesired entry
of xenobiotics and noxae into the human body. While essential for many physiological
processes, this function is a major drawback in brain drug delivery [1]. The fact that viruses are
able to pass the BBB accounts for why research tries to mimic their structure to enable the
targeted delivery of drugs into the brain [2]. By doing so, uptake-relevant virus peptide
sequences are coupled to the surface of nanoparticulate systems. The fate of virus peptide
functionalized drug delivery systems (DDS) is an exciting focal point. Despite the
immobilization of virus-related uptake information on the surface of the DDS, it is questionable
whether such functionalized DDS follow the fate of the virus into the central nervous system
(CNS). The rabies virus glycopeptide (RVG), an external peptide sequence derived from rabies
virus, is said to have a CNS tropism [3]. Therefore, RVG is widely used as ligand for CNS
targeting strategies. However, its use as targeting ligand on DDS requires the modification of
the RVG peptide sequence. Furthermore, the DDS itself has certain characteristics that may
differ from the original rabies virus. The comparison of the rabies virus with RVG-
functionalized DDS with respect to peptide modifications and physicochemical properties
allows an invaluable insight into BBB-targeting strategies (chapter 1).
However, a delivery to the brain is not only a matter of decorating nanoparticulate systems with
specific peptide sequences. The knowledge about tissue-specific requirements of the BBB
together with cutting-edge manufacturing techniques allow for the preparation of tailor-made
nanoparticulate systems with respect to size, surface charge and BBB-penetrating molecules
with enhanced brain uptake. Liposomes were selected as promising candidates for BBB
delivery. By selecting various phospholipids and using a solvent-injection technique [4], several
liposome formulations were prepared to assess the impact of size, surface charge, PEG density
and the usage of the brain specific polyunsaturated fatty acid docosahexaenic acid (DHA) on
the cellular binding of brain endothelial cells (chapter 3).
To our surprise, the analytical characterization of these elaborate formulations is often
overlooked. Although, there are no boundaries set with regard to formulation development of
functionalized liposomes, the analytical characterization of such DDS often lacks the use of
recent analytical techniques such as HPLC. This is a drawback as the manufacturing of
functionalized liposomes is a multi-step process, which requires the analytical tracking of
functionalized phospholipids during manufacturing. Therefore, an HPLC method using
evaporative light scattering detection (ELSD) was developed to simultaneously determine all
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compounds of a PEG containing liposome formulation. The presented method emphasized
HPLC analysis as a powerful technique for the tracking of functionalized phospholipids during
manufacturing. Furthermore, the developed HPLC method allowed the detection of degradation
products (chapter 4).
The functionalization of a liposome requires the use of phospholipids carrying reactive groups
for the covalent coupling of targeting ligands such as virus peptide sequences. The reactivity of
the functional group is hence a prerequisite for the successful binding of the targeting ligand.
Another important factor is that functionalization strategies of liposomes often demand multiple
preparation steps, which may result in delay of the final reaction. This is especially critical for
functional groups, which suffer from activity loss during this process. A prominent example is
the maleimide functionality, which is prone to activity loss due to hydrolysis during
manufacturing. By using an indirect Ellman’s assay, two common preparation methods for
functionalized liposomes, namely pre- and post-insertion method, were analysed with regard to
maleimide stability. The severe impact on maleimide activity was shown with 63% active
maleimide groups for the pre-insertion method and 76% active maleimide groups for the post-
insertion method (chapter 5).
Finally, brain endothelial cells were used to establish a cellular binding model for BBB-specific
liposomes. The physiology of the BBB necessitate specific requirements with regard to size,
surface charge or the use of brain-specific lipids for liposomes. bEnd.3 cells were used to assess
such requirements with respect to physicochemical properties of liposomes. A positive charge
was identified as an important key characteristic for BBB-specific liposomes, while size, PEG
density and the use of the brain-specific polyunsaturated fatty acid DHA had no impact on the
cellular binding of bEnd.3 cells (chapter 6).
Conclusion
On the whole, the presented work addressed neglected points of BBB-targeted delivery. The
direct confrontation of RVG-functionalized DDS with rabies virus clearly revealed the impact
of physicochemical properties on the native fate into the CNS. This unveils the common
assumption of an exclusive uptake due to receptor-ligand interactions and emphasizes the
relevance of the tracking of virus-functionalized DDS under the perspective of a combined
virus-peptide and DDS related uptake strategy. Besides the deep dive into virus-related CNS
targeting strategies, the missing quantitative characterization of such formulations turned out to
be a weak point. Analytical methods need to be established considering how sophisticated these
formulations are and how complex their manufacturing is.
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The application of quantitative methods such as HPLC analysis as well as the determination of
maleimide functionality enable profound process understanding and fulfil the requirement of
today’s standards to DDS. All in all, this work contributes significantly to a better understanding
of the manufacturing and the analysis of BBB-targeted DDS.
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AA Amino acid
AD Alzheimer disease
AD After dialysis
AP After purification
API Active pharmaceutical ingredient
BBB Blood-brain barrier
BCECs Brain capillary endothelial cells
BD Before dialysis
bEND3 Mouse brain endothelical cell line
BHT Butylhydroxy toluene
CNS Central nervous system
CRD Cystein rich domain
CPP Cell penetrating peptide
CHO Cholesterol
DMPC 1,2-Dimyristoyl-sn-glycero-3-phosphocholine
DOPC 1,2-Dioleoyl-sn-glycero-3-phosphocholine
DOPE 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine
DSPE 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine
DSPE-PEG-2000 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (ammonium salt)
DSPE-PEG-2000-Mal 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine-N-
[maleimide(polyethylene glycol)-2000] (ammonium salt)
DTNB 5,5-Dithio-bis-(2-nitrobenzoic acid)
DHA Docosa hexaenic acid
DMEM Dulbecco´s modified eagle medium
DDS Drug delivery system
DLS Dynamic light scattering
EDTA Ethylendiamintetra acetic acid
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ELSD Evaporative light scattering detection
F´Ab Fragment antigen binding
HBSS Hank's Balanced Salt Solution
H2O Water
HPLC High performance liquid chromatography
IG Immunoglobulin
IPA Isopropanol
JEV Japanese encephalitis virus
LUV Large unilamellar vesicle
LDE Laser Doppler Electrophoresis
Lyso-PC Lyso- phosphatidylcholin
MetOH Methanol
MIC Micelle
NCAM Neural cell adhesion molecule
NMJ Neuromuscular junction
NTR Neutrophin receptor
nAchR Nicotinic acetylcholine receptor
p75NTR p75 neutrophin receptor
pDNA Plasma Desoxy ribonucleic acid
PNS Peripheral nervous system
PBS Phosphate buffered saline
PL Phospholipid
PEG Polyethylenglycole
PT Post insertion
RVG Rabies virus glycopeptide
RV-Mat Rabies virus marix protein
RES Reticular endothelial system
SAMSA 5-((2-(and-3)-S-(acetylmercapto) succinoyl) amino) Fluorescein
Abbreviations
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SUV Small unilamellar vesicle
SUV Small unilamellar vesicle
SATA N-succinimidyl S-acetylthioacetate
SD Standard deviation
TFF Tangential flow filtration
TLC Total lipid concentration
TCEP Tris(2-carboxyethyl)-phosphin
ZP Zeta potential
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